ES2242965T3 - DERIVATIVES OF ARIL-ESTER PHOSPHORAMIDATE OF 2 ', 3'-DIDEHYDRONUCLEOSIDS. - Google Patents

Abstract

Aryl substituted phosphoryl derivatives of the formula In which Ar is phenyl, naphthyl, or pyridyl, Y is O or S, X<SUP>1 </SUP>is O, NR<SUP>3</SUP>, S, CR<SUP>3</SUP>R<SUP>4</SUP>, CR<SUP>3</SUP>W<SUP>1 </SUP>or CW<SUP>1</SUP>W<SUP>2</SUP>, X<SUP>2 </SUP>and X<SUP>6 </SUP>are a bond or X<SUP>6 </SUP>is CH<SUB>2 </SUB>and X<SUP>2 </SUP>is O, NR<SUP>3</SUP>, S, CR<SUP>3</SUP>R<SUP>4</SUP>, CR<SUP>3</SUP>W<SUP>1 </SUP>or CW<SUP>1</SUP>W<SUP>2</SUP>, R<SUP>3 </SUP>and R<SUP>4 </SUP>are H, alkyl or phenyl, groups, W<SUP>1 </SUP>and W<SUP>2 </SUP>are heteroatoms, X<SUP>3 </SUP>is alkylene, X<SUP>4 </SUP>is oxygen or CH<SUB>2</SUB>, X<SUP>5 </SUP>is a bond or CH<SUB>2</SUB>, Z is O, NR<SUP>5</SUP>, S, alkyl or phenyl, R<SUP>5 </SUP>is H, alkyl or phenyl, J is H, alkyl, phenyl, or a heterocyclic or polycyclic group, Q is O, NR<SUP>6</SUP>, S, CR<SUP>6</SUP>R<SUP>7</SUP>, CR<SUP>6</SUP>W<SUP>3 </SUP>or CW<SUP>3</SUP>W<SUP>4</SUP>, R<SUP>6 </SUP>and R<SUP>7 </SUP>are H, alkyl or phenyl, and W<SUP>3 </SUP>and W<SUP>4 </SUP>are hetero atoms, T<SUP>1 </SUP>and T<SUP>2 </SUP>are H or CH<SUB>2</SUB>R<SUP>8</SUP>, R<SUP>8 </SUP>is H, OH or F, or T<SUP>1 </SUP>and T<SUP>2 </SUP>together are -CH-CH- or -C(R<SUP>9</SUP>)(R<SUP>10</SUP>)C(R<SUP>11</SUP>)(R<SUP>12</SUP>)-, R<SUP>9 </SUP>is H, halogeno, CN, NH<SUB>2</SUB>, CO-alkyl, or alkyl, R<SUP>10</SUP>, R<SUP>11</SUP>, and R<SUP>12 </SUP>are H, N<SUB>3</SUB>, halogen, CN, NH<SUB>2</SUB>, CO-alkyl, or alkyl, and B is a purine or pyrimidine base, have antiviral activity, as for example against HIV. Particularly preferred are thymine and adenine derivatives of amino acid phenoxyphosphoroamidates. A typical embodiment is 2',3'-dideoxy-2',3'-didehydrothymidine 5'-(phenyl methoxy alaninyl) phosphoroamidate which can be prepared from phenyl methoxy alaninyl phosphorochloridate and 2',3'-dideoxy-2',3'-didehydrothymidine.

Description

Aryl ester phosphoramidate derivatives of 2 ', 3'-didehydronucleosides.

The present invention relates to a new class of nucleoside analogues and their therapeutic use in the prophylaxis and treatment of viral infection, for example by the human immunodeficiency virus (HIV), which is believed to be the etiologic agent in acquired immunodeficiency syndrome (AIDS).

There has been much interest in the use of nucleoside analogs as HIV inhibitors. 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine (d4T) and 3'-azido-3'-deoxythymidine (AZT) are both known HIV inhibitors [Hitchcock et al., Antiviral Chem. Chemother. (1991), 2 , 125; Mansuri et al., Antimicrob. Agents Chemother., (1990), 34 , 637]. It is conventionally thought that HIV inhibition by these, and other nucleoside analogs, depends on the conversion of the nucleoside analog in vivo into the corresponding 5'-triphosphate by the kinase enzymes (of the host cell). However, this absolute dependence on kinase-mediated activation (of the host cell) can lead to poor activity, the emergence of resistance, and clinical toxicity.

In order to reduce the dependence of the kinase enzymes, the use of masked phosphate pro-drugs of bioactive nucleotide forms of numerous chemotherapeutic nucleoside analogs has been suggested.
[McGuigan et al., Nucleic Acids res., (1989), 17 , 6065; McGuigan et al., Idem., (1989), 17 , 7195; Chawla et al., J. Med. Chem., (1984), 27 , 1733; Sergheraert et al., J. Med. Chem. (1993), 36 , 826-830]. In particular, McGuigan et al [J. Med. Chem. 36 , 1048-1052 (1993)] have reported on the preparation of aryl ester derivatives of AZT phosphoramidate. In vitro evaluation of these compounds revealed that the compounds had anti-HIV activity. However, in "normal" thymidine kinase-rich cells (TK +), the activity of such compounds was at least an order of magnitude less than the nucleoside of AZT origin. Only TK-deficient cells (TK -), in which the activity of the aryl ester derivatives of phosphoramidate was virtually maintained but the activity of AZT was reduced, the activity of the derivatives exceeded that of AZT.

McGuigan et al. [Bioorganic & Medical chemistry Letters., 3 (6), 1203-1206 (1993)] have also reported on the preparation of trésterfosphate derivatives of d4T. Again, in vitro evaluation of these compounds revealed that while the compounds have significant anti-HIV activity, the activity is less than that of the nucleoside of d4T origin in TK + cells.

Abraham and Wagner (Nucleosides and Nucleotides 13 (9) , 1891-1903 (1994)) have reported the preparation of diesters and tri-esters phosphoramidate nucleosides but do not report any biological activity.

It has been shown that the acyclic nucleoside analog 9 (2-phosphonomethoxyethyl) adenine (PMEA), and analogues thereof show activity against herpes viruses and retroviruses including HIV (Calio et al., Antiviral Res., (1994), 23 (1) , 77-89; Balzarini et al., AIDS, (1991), 5 (1) , 21-28).

McGuigan et al. [FEBS Letters 351 (1994) 11-14] have reported certain tri-ester phosphate derivatives of the inactive nucleoside analogue, dideoxyuridine, are inhibitors of HIV replication at µM levels.

To date, the approach to provide masked phosphate pro-drugs have failed to intensify the anti-viral activities of nucleoside analogs of origin such as AZT and d4T in TK + cells. In addition, the emergence of resistance to nucleoside analogs in its 5'-triphosphate form bioactive has returned the phosphate prodrugs masked referrals and their nucleoside analogs of potentially origin ineffective

It has now been found that a specific class of masked nucleoside analogs are very viral inhibitors potent in both TK - and TK + cells, and still retain activity against nucleoside resistant viruses (e.g. d4T).

According to the present invention a compound of formula (1):

one

where:

Ar is a group aryl;

And it is oxygen or sulfur;

X1 se selects between O, NR 3, S, CR 3 R 4, CR 3 W 1 and CW 1 W 2 where R 3 and R 4 are selected

independently between hydrogen, groups alkyl and aryl; and W1 and W2 are heteroatoms;

X 6 is CH2 and X2 is selected (independently of X1) between O, NR 3, S, CR 3 R 4, CR 3 W 1 and CW 1 W 2

where R3 and R 4 are independently selected from hydrogen, groups alkyl and aryl; and W1 and W2 are heteroatoms;

X3 is -CR 1 R 2 - where R 1 and R 2 are selected independently between hydrogen, alkyl and aryl groups; X 4 it is oxygen;

X5 is absent;

Z is selected between O and NR 5, where R 5 is selected from hydrogen, alkyl and aryl groups;

J is selected between the alkyl groups;

Q is selected between O, NR 6, S, CR 6 R 7, CR 6 W 3 and CW 3 W 4, where R 6 and R 7 are selected

independently between hydrogen, groups alkyl and aryl; and W3 and W4 are heteroatoms;

T1 and T2 are linked together and together are selected from among groups

2

B is a base of purine or pyrimidine

or a derivative or metabolite pharmaceutically acceptable from same.

The compounds of the present invention are potent anti-viral agents. In particular, they are very effective against HIV in both TK - and TK + cells. Particularly surprising is the activity of the compounds of the present invention against nucleoside resistant HIV. These observations indicate that the activity of these compounds does not It is totally dependent on the conventional mode of action (requiring hydrolysis of the aryl phosphate ester bonds and P-X1 followed by conversion dependent on kinase in the 5'-triphosphate derivative), but It arises from a completely different mode of action. The data Experimental presented here indicate that the compounds and metabolites of the present invention act directly as reverse transcriptase (RT) inhibitors via a route metabolic and a mechanism of action not previously recognized.

The reference herein to a group alkyl represents a linear or branched hydrocarbyl radical, cyclic or acyclic, saturated or unsaturated (e.g. alkenyl or alkynyl). When it is cyclic, the alkyl group is preferably C 3 to C 12, more preferably C 5 to C 10, more preferably C 5 to C 7. When it is acyclic, the group alkyl is preferably C 1 to C 16, more preferably C 1 to C 6, more preferably methyl. The reference in the present memory to alkoxy and aryloxy groups represents groups alkyl-O- and aryl-O, respectively. Reference to alkoxy and aryloyl groups represents alkyl-CO- and -aryl-CO-, respectively.

The reference herein to a group aryl represents an aromatic group, such as phenyl or naphthyl, or a heteroaromatic group containing one or more, preferably a, heteroatom, such as pyridyl, pyrrolyl, furanyl and thiophenyl. Preferably, the aryl group comprises phenyl or phenyl replaced.

The alkyl and aryl groups can be substituted or unsubstituted, preferably unsubstituted. When they are substituted, preferably 1 to 3 will be present substituents, preferably 1 substituent. Between the substituents can include halogen atoms and groups halomethyl such as CF 3 and CCl 3; groups that contain oxygen such as oxo, hydroxy, carboxy, carboxy alkyl, alkoxy, alkoxy, alkoxy, aryloxy, aryloyl and aryloxy; groups that contain nitrogen such as amino, alkylamino, dialkylamino, cyano, azide and nitro; sulfur-containing groups such as thiol, alkylthiol, sulfonyl and sulfoxide; heterocyclic groups that can be substituted in turn; alkyl groups, which may be at your once replaced; and aryl groups, which may be in turn substituted, such as phenyl and substituted phenyl. In rent it include substituted and unsubstituted benzyl.

The reference herein to groups heterocyclic represents groups containing one or more of, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, tetrahydrofuranyl, pyranyl, pironyl, pyridyl, pyrazinyl, pyridazinyl, piperidyl, piperazinyl, morpholinyl, thionaphthyl, benzofuranyl, isobenzofuryl, indolyl, oxyindolyl, isoindolyl, indazolyl, indolinyl, 7-azaindolyl, isoindazolyl, benzopyranyl, coumarinyl, isocumarinyl, quinolyl, isoquinolyl, naphthyridinyl, cinolinyl, quinazolinyl, pyridopyridyl, benzoxazinyl, quinoxadinyl, chromenyl, chromanyl, isochromanyl and carbolinyl

References herein to groups polycyclics represent a group comprising two or more rings carbocyclic or non-aromatic heterocyclics that may be at your once replaced.

The reference herein to halogen represents a fluorine, chlorine, bromine or iodine radical, preferably a fluorine or chlorine radical.

The Ar group comprises a substituted or unsubstituted aryl group, where the term "aryl group" and the possible substitution of said group are defined as before. Preferably, Ar is a substituted or unsubstituted phenyl group. Particularly preferred substituents are the removable groups of choice such as halogens (preferably chlorine or fluorine), trihalomethyl (preferably trifluoromethyl), cyano and nitro groups. Preferably, Ar is phenyl, 3,5-dichlorophenyl, p- trifluoromethylphenyl, p- cyanophenyl, or p- nitrophenyl.

And it can be oxygen or sulfur. Preferably, Y It is oxygen.

X 1 is selected from O, NR 3, S, CR 3 R 4, CR 3 W 1 and CW 1 W 2 where R 3 and R 4 are independently selected from hydrogen, alkyl and aryl groups; and W1 and W2 are heteroatoms. Preferably, X 1 is selected from O, S and NR 3. Preferably, X 1 is NR 3. When present, R 3 is preferably H. When present, W 1 and W 2 can independently comprise any heteroatom such as a halogen, preferably
fluorine.

X 6 is CH 2, and X 2 is selected (independently of X 1) between O, NR 3, S, CR 3 R 4, CR 3 W 1 and CW 1 W 2 where R 3 and R 4 are independently selected from H, alkyl groups and aryl; and W1 and W2 are heteroatoms. When present, X 2 is preferably oxygen. When present, R3 it is preferably H. When W 1 and W 2 are present independently comprise any heteroatom such as halogen, preferably fluorine.

X 4 is oxygen.

X 5 may be absent or is CH 2.

Z may comprise O or NR 5, where R 5 is Select between H, alkyl and aryl groups. Preferably, Z is O or NR5. Preferably, R 5 is hydrogen. Very preferably, Z is oxygen.

J is a substituted or unsubstituted alkyl group. Preferably, J is an alkyl group C 1 -C 6 substituted or unsubstituted, preferably a benzyl or methyl group.

X 3 is a CR 1 R 2 group where R 1 and R2 are independently selected from hydrogen, groups alkyl and aryl. Preferably, at least one of R1 and R2 It is hydrogen. It will be appreciated that if R 1 and R 2 are different, The carbon atom to which they are attached is an asymmetric center. The stereochemistry on this site can be R or S or mixed. When one of R 3 and R 4 is hydrogen, the stereochemistry is preferably S.

Q is selected from O, NR 6, S, CR 6 R 7, CR 6 W 3 and CW 3 W 4, where R 6 and R 7 are independently selected from hydrogen, groups alkyl and aryl; and W 2 and W 3 are heteroatoms such as halogen atoms, preferably fluorine. Preferably, Q is O, S, CH2 or CF2. Most preferably, Q is oxygen.

T1 and T2 are linked together and form together the group:

3

B comprises a purine or pyrimidine base, such such as adenine, thymine, uracil, cytosine or guanine and derivatives of the same. Derivatives thereof include bases of substituted purine or pyrimidine where the substituents are defined like before. Examples of substituted bases include the substituted pyrimidine in position 5. Preferably B is adenine or thymine.

       \ newpage
    

Preferably, the present invention provides a compound of formula (2)

4

where Ar, R1, J, X2, X 5, X 6, Q, T 1, T 2 and B are defined as before; or a derivative or metabolite thereof pharmaceutically acceptable.

It will be appreciated that the group -NH-CHR 1 -CO 2 J corresponds to an α-amino acid with the protected carboxy group. Preferably, the R 1 group corresponds to the side chain of a naturally occurring amino acid such as Alanine, Arginine, Asparagine, Aspartic acid, Cysteine, Cystine, Glycine, Glutamic acid, Glutamine, Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Proline, Serine, Threonine, Tryptophan, Tyrosine, Valine. Preferably, R 1 is Me or PhCH 2 corresponding to the side chain of alanine or phenylalanine, respectively. Preferably, the stereochemistry at the asymmetric center -CHR1-asymmetric corresponds to an L- amino acid.

According to a preferred embodiment, the present Invention provides a compound of formula (3):

       \ vskip1.000000 \ baselineskip
    

5

where Ar, Y, X 1, X 2, X 3, X 4, Z, Q and B are defined as before.

More preferably, the invention provides a compound according to formula (3), of formula (4):

6

where Ar, R1 and J are defined like before; or a pharmaceutically acceptable derivative or metabolite of the same. Preferably, the invention provides a compound of formula (4) in which Ar, R1 and J are defined according to the Table one.

TABLE 1

Compound from Reference Ar R1 J 323 4-EtPh I I 324 Ph I I 327 4-FPh I I 526 3-CF 3 Ph I I 546 3,5-Cl2 Ph I I 730 Ph I Bzl 776 2,4-Br2 Ph I I 779 F_5 Ph I I 862 Ph I Hexyl 863 Ph Bzl I 864 Ph CH_ {2} iPr I 865 Ph iPr I 866 Ph H I 867 Ph [CH 2] 2 SMe I 868 2,4Br2 Ph I Bzl 877 Ph Bzl Bzl 878 Ph Bzl tBu 892 Ph I Cyclohexyl 893 Ph I tBu 1078 Ph CH 2 CO 2 H I 1214 Ph CH 2 CH 2 CH 2 NHC [NH 2] NH I 1218 Ph I n-Pent 1219 Ph I neo-Pent 1226 Ph I 1-Naphthyl 1227 Ph I 2-Naphthyl

A characteristic of the aryl ester phosphate compounds (1) of the present invention is that they show significantly enhanced anti-viral efficacy, both in vitro and in vivo assays , compared to their corresponding nucleoside analogue (9)

7

In addition, the compounds of the present invention show a significantly reduced toxicity compared with their corresponding analogues (9).

The compounds of the present invention show therefore a highly intensified selectivity index (reason of CC 50 (toxicity): EC 50 (activity)) compared to its corresponding nucleoside analog.

Experiments with radiolabeled compounds of the present invention have shown that the compounds produce intensified intracellular levels of nucleosides 5'-triphosphate, being the intensification particularly significant in TK - cells. That way, the compounds of the present invention may act in part through the known metabolic pathway.

However, it has been discovered that the compounds of the present invention show a surprising activity against to HIV-resistant nucleoside strains. This indicates that the compounds of the present invention also act by a independent path of a metabolite 5'-triphosphate.

It has been shown that the compounds of the present invention lead to the intracellular generation of elevated levels of a metabolite (10).

8

The metabolite (10) can also be prepared by treatment of the corresponding compound according to the formula (1) with pig liver esterase. On the other hand, it has shown that the compounds of formula (10) are inhibitors Direct HIV reverse transcriptase.

According to an additional aspect of the present invention is provided a compound of formula (10)

9

where Ar, Y, X 1, X 2, X 3, X 4, X 6, T 1, T 2, Q, X 5 and B are defined as before, or a pharmaceutically derived or metabolite acceptable from same.

The intracellular generation of metabolites anti-virals such as (10) is an important characteristic of the invention for numerous reasons. In first instead, the direct activity of (10) on RT eliminates the need for nucleotide kinase mediated phosphorylation additional, which can be slow in many cases. In cases in that the nucleoside phosphate is not a substrate for nucleotides host kinases, activation will be poor and efficacy low anti-viral, even if triphosphate is a excellent RT inhibitor. In such cases, the generation of metabolites such as (10) can lead to a very high increase significant antiviral action. Such compounds can act directly in its own right or through a product of transposition, decomposition or disproportion or by means of a pollutant. Moreover, the structure of such metabolites as (10) it can be additionally designed to optimize the joint to the known structure of RT, and similar metabolites modified could be released intracellularly using the technology described here, to further intensify the effect anti-viral

By "pharmaceutically acceptable derivative" any salt, ester or salt of such an ester is represented pharmaceutically acceptable or any other compound that after administration to a recipient be able to provide (direct or indirectly) a compound of formula (1) or (10). By "pharmaceutically acceptable metabolite" represents a metabolite or remainder of a compound of formula (1) or (10) that originates a reverse transcriptase inhibition mode independent of nucleoside resistance or nucleoside independent 5'-triphosphate shown by the compounds of formula (1) or (10).

According to an additional aspect of the present invention a compound according to the present invention is provided for use in a treatment method, preferably in the prophylaxis or treatment of viral infection.

According to an additional aspect of the present invention the use of a compound according to the present is provided invention in the manufacture of a medicament for prophylaxis or The treatment of viral infection.

A compound according to the present invention can be employed in a method of prophylaxis or treatment of viral infection comprising administration to a patient who need such treatment of an effective dose of compound.

The viral infection can comprise any viral infection such as HIV and herpes virus, including HSV 1 and HSV 2, CMV, VZV, EBV, HAV, HBV, HCV, HDV, papilloma, rabies and influenza.

Preferably, the viral infection comprises the HIV infection, more preferably HIV-I or HIV-II It is a feature of the present invention that the compounds show a good activity both against HIV-I as HIV-II.

According to an additional aspect of the present invention the use of a compound of the present is provided invention in the manufacture of a medicament for use in the inhibition of a reverse transcriptase through a mode of action independent of nucleoside resistance or independent of 5'-triphosphate nucleoside.

According to an additional aspect of the present invention is provided a pharmaceutical composition comprising a compound of the present invention combined with an excipient pharmaceutically acceptable.

According to an additional aspect of the present invention is provided a method of preparing a composition pharmaceutical comprising the step of combining a compound of the present invention with a pharmaceutically excipient acceptable.

The medications used herein invention can be administered by oral routes or parenteral, including intravenous, intramuscular administration, intraperitoneal, subcutaneous, transdermal, upstream (aerosols), rectal, vaginal and topical (including oral and sublingual)

For oral administration, the compounds of the invention will generally be provided in the form of tablets or capsules, in the form of powder or granules, or in the form of a solution or aqueous suspension

Tablets for oral use may include the active ingredient mixed with pharmaceutically excipients acceptable such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservatives. Between the Suitable inert diluents include sodium carbonate and calcium, sodium phosphate and calcium, and lactose, while the starch of Corn and alginic acid are suitable disintegrating agents. Between the binding agents can include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc. If desired, the tablets can be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay Absorption in the gastrointestinal tract.

Among the capsules for oral administration are include hard gelatin capsules in which the ingredient active is mixed with a solid inert diluent, and capsules soft gelatin in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin or oil made of olives.

Formulations for rectal administration they can be presented in the form of a suppository with a base suitable comprising for example cocoa butter or a salicylate.

The right formulations for Vaginal administration can be presented in the form of pessaries, buffers, creams, gels, pastes, foams or formulations for spray containing in addition to the active ingredient carriers such as those known in the art for being appropriate.

For intramuscular, intraperitoneal use, subcutaneous and intravenous, the compounds of the invention are they will generally provide in aqueous solutions or suspensions sterile, buffered at an appropriate pH and isotonicity. Between the Suitable aqueous vehicles include Ringer's solution and chloride of isotonic sodium. Among the aqueous compositions according to the invention suspending agents such as derivatives may be included of cellulose, sodium alginate, polyvinylpyrrolidone and gum tragacanth, and a wetting agent such as lecithin. Between the Suitable preservatives for aqueous suspensions are included ethyl p-hydroxybenzoate and n-propyl.

The compounds of the invention can also be present in the form of liposome formulations.

In general an adequate dose will be in the range of 0.1 to 300 mg per kilogram of body weight of the receptor per day, preferably in the range of 6 to 150 mg per kilogram of body weight per day and most preferably in the range of 15 to 100 mg per kilogram of body weight per day. The Desired dose is preferably presented in the form of two, three, four, five or six or more sub-doses administered at intervals appropriate throughout the day. These subdoses can be administered in unit dosage forms, for example, containing 10 to 1500 mg, preferably 20 to 1000 mg, and very preferably 50 to 700 mg of active ingredient per form unit dosage.

According to an additional aspect of the present invention is provided a process for the preparation of a compound according to the present invention, the process the reaction of a compound of formula (11)

10

with a compound of formula (12)

eleven

The reaction can be carried out in tetrahydrofuran in the presence of N-methylimidazole

The invention will now be described with reference to the following Figures and Examples. It will be appreciated that that follows is only by way of example and that can be done modifications to detail while still within the scope of the invention.

Figure 1 illustrates the in vivo antiviral activity of d4T (comparative) and the aryl ester phosphoramidate compound of 324 in MSV infected mice. The drug doses are 50 [low] or 200 [high] mg / kg / day administered ip for 4 days starting 1 hour before inoculation with MSV.

Experimentation

All experiments involving water sensitive compounds were carried out under scrupulously dry conditions. Tetrahydrofuran was dried by heating under reflux over sodium and benzophenone followed by distillation and storage on active sieves. The N-methylimidazole was purified by distillation. The nucleosides were dried at an elevated temperature in vacuo over P2O5. The proton, carbon and phosphorus Nuclear Magnetic Resonance spectra (rmn H 1, C 13, P 31) were recorded on a Bruker Avance DPX spectrometer operating at 300 MHz, 75.5 MHz , and 121.5 MHz respectively. All rmn spectra were recorded in CDCl3 at room temperature (20 ° C +/- 3 ° C). The chemical shifts of H 1 and C 13 were expressed in parts per million under the tetramethylsilane field. The values of J refer to the coupling constants and the signal decay patterns are described as singlet (s), singlet width (s width), doublet (d), triplet (t), quartet (c), multiplet (m) or combinations thereof. The chemical shifts of P31 are expressed in parts per million in relation to an external phosphoric acid pattern. Many NMR peaks were further disintegrated due to the presence of diastereoisomers in the [chiral] phosphate center. Chromatography refers to flash column chromatography and was carried out using Merck 60H silica gel (40-60 m, 230-400 mesh) as the stationary phase. Thin layer chromatography was performed using silica plates with the aluminum back Alugram SIL G / UV 254.

Mass spectra were recorded by fast atom bombardment mode (FAB) on a VG spectrometer 70- -250. HPLC data was recorded using a ACS quaternary system with an ODS5 column and an eluent of water / acetonitrile, with 0-10 mm of 82% water, and then a linear gradient of 20% water for 30 min, with a flow rate of 2 ml / min and UV detection at 265 nm.

Test compounds were isolated in form of mixtures of diastereoisomers, this isomerism arising from the mixed stereochemistry in the phosphate center. Oils resulting did not give useful microanalytical data but it was found that were pure by high multinuclear NMR spectroscopy field and analysis by rigorous HPLC.

Compound Preparation

The compounds of the present invention were prepared according to the following general procedures.

Preparation of aryl phosphorodichloridates (procedure general)

A solution of the appropriate phenol (30.4 mmol) and triethylamine (4.25 ml, 30.5 mmol) in dry CH2Cl2 (25 ml) was added to a solution of freshly distilled POCl3 (10 ml, 107 mmol) in CH 2 Cl 2 (30 ml) at -50 ° C and the mixture was stirred at the room temperature overnight. The reaction mixture is filtered and the filtrate was evaporated. Ether (20 ml) was added and The precipitated product was filtered again. After evaporation the residue was distilled if possible.

Phenyl N-methylalaninyl phosphorochloridate

A solution of triethylamine (1 ml - 7.17 mmol) in 15 ml of dry CH2Cl2 was added dropwise to a mixture of phenyl phosphorodichloridate (757.4 mg, 3.59 mmol) and hydrochloride of L-alanine methyl ester (500 mg, 3.58 mmol) in 50 ml of dry CH 2 Cl 2 at -80 ° C in one hour. The mixture was then stirred vigorously at -50 ° C for five hours and the CH2Cl2 was evaporated. 25 ml of dry ether was added and the precipitated product was filtered off under nitrogen. Evaporation of the ether gave a colorless oil that was used without further purification for the next
stage.

Preparation of aryl phosphate nucleoside analogues (general procedure)

Phenyl N-methylalaninyl was added phosphorochloridate (250 mg, 0.9 mmol, 2.0 equiv.) to a solution agitated nucleoside analog 0.45 mmol) and N-methylimidazole (0.37 ml, 143.5 µL, 1.8 mmol, 4 equiv.) In THF (2 ml). After 4 hours, the solvent was removed under reduced pressure. The gum was dissolved in chloroform (10 ml), and was washed with 1M HCl (8 ml), sodium bicarbonate (10 ml) and water (15 ml). The organic phase was dried, and the solvent was removed in vacuo. He residue was purified by chromatography on silica eluting with chloroform-methanol (97: 3). The meeting and the evaporation of the solvent gave the product as a solid White color.

Spectra data 323 - 5 '- (p-Ethylphenylmethoxy-alaninyl) phosphoramidate from 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Yield = 79%

P 31 (CDCl 3): 3.43 ppm

H 1 (CDCl 3): 9.25 (0.5H, s, B, NH), 9.23 (0.5H, s, A, NH), 7.34 (0.5H, s, 11-6, B), 7.33 (0.5H, s, H-6, A), 7.14-7.00 (5H, m, Ph, H-1 '), 6.28 (1H, m, H-3'), 5.88 (1H, m, H-2 '), 5.00 (1H, m, H-4'), 4.38-4.25 (2H, m, H-5 '), 3.93 (2H, m, NH-wing, CH-wing), 3.70 (1.5H, s, OMe, A), 3.67 (1.5H, s, OMe, B), 2.60 (2H, c, CH2CH3, J = 7.5 Hz), 1.84 (1.5H, d, 5-CH 3, J = 1.2 Hz), 1.80 (1.5H, d, 5-CH3, J = 1.2 Hz), 1.31 (3H, m, CH 2 CH 3, 1.19 (3H, m, ala-CH 3).

C 13 (CDCl 3): 174.25 (wing-CO, A), 174.12 (wing-CO, B), 164.22 (C-4, B), 164.17 (C-4, A), 151.15 (C-2, B), 151.12 (C-2, A), 148.29 (i-Ph, B), 148.16 (i-Ph, A), 141.24 (p-Ph, A), 141.19 (p-Ph, B), 136.06 (C-6, B), 135.76 (C-6, A), 133.50 (C-3 ', A), 133.15 (C-3', B), 129.11 (o-Ph, A), 129.05 (o-Ph, B), 127.54 (C-2 ', A), 127.36 (C-2', B), 120.08 (d, m-Ph, B, J = 3.9 Hz), 119.90 (d, m-Ph, A, J = 4.9 Hz), 111.51 (C-5, A), 111.40 (C-5, B), 89.83 (C-1 ', B), 89.60 (C-1 ', A), 84.88 (d, C-4', B, J = 8.8 Hz), 84.70 (d, C-4 ', A, J = 8.8 Hz), 67.11 (d, C-5 ', A, J = 4.9 Hz), 66.48 (d, C-5', B, J = 4.9 Hz), 52.65 (OMe), 50.26 (wing-CH, B), 50.13 (ala-CH, A), 28.19 (Ph-CH2), 20.97 (d, ala-CH 3, B, J = 4.9 Hz), 20.90 (d, ala-CH 3, A, J = 4.9 Hz), 15.69 (Ph-CH 2 CH 3), 12.45 (5-CH 3, A), 12.41 (5-CH 3, B).

MS: C 22 H 29 N 3 O 8 P: 494 (MH <+>, 5), 368 (MH <+> - thymine, 25), 228

(15), 81 (C 5 H 5 O, base peak) Mass exact: expected 494.1692; found 494.1693

HLC: RT = 27.23 and 27.48 min

324 - 5 '- (Phenyl-N-methoxyalaninyl) phosphoramidate from 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Yield = 88%

P 31 (CDCl 3): 3.20 and 3.86 ppm

H 1 (CDCl 3): 1.32 and 1.34 (d, 3H, J = 6.8Hz, CH 3 wing); 1.81 and 1.84 (d, 3H, 5CH3); 3.69 and 3.70 (s, 3H, OMe); 3.84-4.00 (m, 2H, CH wing + NH wing); 4.32 (m, 2H, H5 '); 5.02 (m, 1H, H4 '); 5.88 (m, 1H, H2 '); 6.33 (m, 1H, H3 '); 7.03 (m, 1H, H1 '); 7.15-7.35 (m, 6H, Ar + H6); 9.22 and 9.26 (wide s, 1H, NH)

C 13 (CDCl 3): 12.52 (5CH 3); 21.02 (CH 3 wing); 50.22-50.35 (CH wing); 52.74 COMe); 66.62-67.29 (C5 '); 84.80-84.88 (C4 '); 89.69-89.93 (C1 '); 111.44-111.57 (C5); 120.13-120.31 (Ar ortho); 125.30 (Ar for); 127.49-127.65 (02 '); 129.87-129.93 (Ar meta); 133.19-133.50 (C3 '); 135.77-136.06 (C6); 150.51 (Ar ipso); 151.16 (C2); 164.14 (C4); 174.12 (Co to)

MS: 466 (MH + 0, 7) 340 (MH + 0 -base); 200 (17); 136 (47); 89 (25); 81 (C 5 H 5 O, base peak)

HPLC: RT = 22.48 and 22.87 min

327-5'- (p-Fluorophenyl-methoxyalaninyl) -phosphoramidate from 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Yield = 89%

P 31 (CDCl 3): 3.16 ppm

H 1 (CDCl 3): 9.75 (1H, s, NH), 7.24 (0.5H, d, H-6, B, J = 1.2 Hz), 7.17 (0.5H, d, H-6, A, J = 1.2 Hz), 7.09 (5H, m, Ph, H-1 '), 6.22 (1H, m, H-3'), 5.82 (1H, m, H-2 '), 4.94 (1H, m, H-4'), 4.30-3.84 (4H, m, wing-NH, CH-wing, H-5 '), 3.63 (1.5H, s, OMe, A), 3.62 (1.5H, s, OMe, B), 1.77 (1.5H, d, 5-CH 3, B, J = 1.0 Hz), 1.74 (1.5H, d, 5-CH 3, A, J = 1.0 Hz), 1.29 (1.5H, d, ala-CH 3, B, J = 7.0 Hz), 1.23 (1.5H, d, ala-CH 3, A, J = 7.0 Hz).

C 13 (CDCl 3): 174.19 (d, wing-CO, B, J = 6.8 Hz), 174.00 (d, wing-CO, A, J = 6.8 Hz), 164.25 (C-4, B), 164.20 (C-4, A), 159.77 (d, p-Ph, J = 243.6 Hz), 151.14 (C-2), 146.25 (i-Ph), 125.99 (C-6, A), 135.70 (C-6, B), 133.40 (C-3 ', A), 133.05 (C-3 ', B), 127.61 (C-2', B), 127.45 (C-2 ', A), 121.70 (m, o-Ph), 116.37 (d, m-Ph, A, J = 23.5 Hz), 116.34 (d, m-Ph, B, J = 23.5 Hz), 111.45 (C-5, A), 111.32 (C-5, B), 89.87 (C-1 ', A), 89.63 (C-1 ', B), 84.66 (d, C-4', J = 5.9 Hz), 67.29 (d, C-5 ', A, J = 4.9 Hz), 66.10 (d, C-5 ', B, J = 4.9 Hz), 52.70 (OMe), 50.26 (wing-CH, A), 50.13 (wing-CH, B), 20.92 (d, ala-CH 3, A, J = 4.8 Hz), 20.88 (d, ala-CH 3, B, J = 4.8 Hz), 12.45 (5-CH 3, B), 12.41 (5-CH 3, TO).

MS: C 20 H 24 N 3 O 8 PF: 484 (MH +, 11), 358 (MH + - thymine, 20), 218 (13), 154 (32), 136 (28), 81 (C 5 H 5 O, base peak). Mass exact: expected 484,1285; found 484.1318

HPLC: RT = 25.17 and 25.40 min

526 - 5 '- (m-Trifluoromethylphenyl-methoxyalaninyl) -phosphoramidate from 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Yield = 80%

P 31 (CDCl 3): 2.49 and 3.16 ppm

H 1 (CDCl 3): 9.06 (1H, s, NH), 7.45 (5H, m, H-6, Ph), 7.03 (1H, m, H-1 '), 6.31 (1H, m, H-3 '), 5.92 (1H, m, H-2 '), 5.03 (1H, m, H-4'), 4.32 (2H, m, H-5 '), 3.97 (2H, m, NH-wing, CH-wing), 3.71 (1.5H, s, OMe, B), 3.70 (1.5H, s, OMe, A), 1.86 (1.5H, s, 5-CH3, B), 1.80 (1.5H, d, 5-CH 3, A), 1.36 (3H, m, ala-CH 3).

C 13 (CDCl 3): 174.06 (d, ala-CO, A, J = 6.8 Hz), 173.89 (d, wing-CO, B, 5 = 6.8 Hz), 163.91 (C-4, A), 163.86 (C-4, B), 150.96 (C-2), 150.71 (d, a-Ph, J = 5.9 Hz), 135.86 (C-6, A), 135.66 (C-6, B), 133.30 (C-3 ', A), 133.02 (C-3', B), 132.00 (c, c-Ph, J = 32.0 Hz), 130.66 (e-Ph), 127.84 (C-2 ', B), 127.74 (C-2 ', A), 123.98 (f-Ph, A), 123.84 (g, CF 3, J = 272.0 Hz), 123.79 (f-Ph, B), 122.14 (d-Ph), 117.54 (d, b-Ph, J = 3.9 Hz), 111.61 (C-5, B), 111.44 (C-5, A), 90.04 (C-1 ', B), 89.77 (C-1', A), 84.61 (d, C-4 ', J = 7.8 Hz), 67.60 (d, C-5 ', B, J = 4.9 Hz), 66.89 (d, C-5', A, J = 4.9 Hz), 52.87 (OMe), 50.32 (d, wing-CH, A, J = 4.8 Hz), 50.26 (d, ala-CH, B, J = 4.8 Hz), 21.11 (d, ala-CH 3, B, J = 4.9 Hz), 20.99 (d, ala-CH 3, A, J = 4.9 Hz), 12.55 (5-CH 3, B), 12.47 (5-CH 3, TO).

MS: C 21 H 24 N 3 O 8 PF 3: 534 (MH <+>, 6), 408 (MH <+> - thymine, 8), 268 (10), 149 (10), 81 (C 5 H 5 O, base peak). Exact mass: expected 534,1253; found 534.1201

HPLC: RT = 30.56 min

546 - 5 '- (3,5-Dichlorophenyl-methoxyalaninyl) -phosphoramidate from 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Yield = 70%

P 31 (CDCl 3) 2.83 and 3.42 ppm

(CDCl3): 9.74 (1H, s, NH), 7.40 (1H, s, H-6), 7.29 (3H, m, Ph), 7.14 (1H, m, H-1 '), 6.44 (1H, m, H-3'), 6.04 (1H, m, H-2 '), 5.14 (1H, m, H-4'), 4.48-4.07 (5H, m, wing-NH, CH-wing, H-5 '), 3.84 (3H, s, OMe), 1.97 (1.5H, s, 5-CH3, A), 1.92 (1.5H, s, 5-CH 3, B), 1.48 (3H, m, ala-CH 3).

C 13 (CDCl 3) 173.93 (wing-CO), 164.09 (C-4), 151.27 (i-Ph), 151.06 (C-2), 136.01 (m-Ph), 135.60 (C-6), 133.14 (C-3 ', B), 132.89 (C-3', A), 127.83 (C-2 '), 125.69 (p-Ph), 119.40 (o-Ph), 111.54 (C-5, A), 111.40 (C-5, B), 90.03 (C-1 ', A), 89.74 (C-1 ', B), 84.60 (C-4'), 67.68 (C-5 ', A), 66.98 (C-5', B), 52.85 (OMe), 50.26 (ala-CH), 20.93 (wing-CH 3), 12.51 (5-CH 3).

MS: C 20 H 23 N 3 O 8 PCl 2: 534 (MH +, 8), 408 (MH + - thymine, 12), 391 (10), 149 (12), 127 (thymineH +, 12), 81 (C5H5O, peak base).

Exact mass: expected 534.0600; found 534,0589

HPLC: RT = 32.19 min

730 - 5 '- (Phenyl-N-benzyloxyalaninyl) phosphoramidate from 2'3'-dideoxy-2 ', 3'-dideshydrotimidine

Yield = 92%

P 31 (CDCl 3) 3.40 and 4.04 ppm

H 1 (CDCl 3) 1.24 and 1.26 (d, 3H, J = 6.8Hz, CH 3 wing); 1.70 and 1.74 (s, 3H, 5CH3); 3.86-4.28 (m, 4H, H5 '+ CH wing + NH); 4.85 (m, 1H, H4 '); 5.04 and 5.06 (s, 2H, CH2 Ph); 5.74 (d, 1H, H2 '); 6.16 (dd, 1H, H3 '); 6.90 (m, 1H, H1 '); 7.00-7.30 (m, 11H, Ar + H6); 9.61 (d, 1H, NH)

C 13 (CDCl 3): 12.52 (5CH 3); 20.98 (CH 3 wing); 50.36-50.52 (CH wing); 66.70-67.18 (C5 '); 67.46 (CH2 Ph); 84.63-84.76-84.88 (C4 '); 89.68-89.88 (C1 '); 111.44-111.55 (C5); 120,18-120,25-120,36-120.43 (Ar ortho, OPh); 125.31 (Ar para, OPh); 127.48-127.61 (C2 '); 128.45-128.79-128.83 (Ar, CH2 Ph); 129.87-129.93 (Ar meta, OPh); 133.16-133.45 (C3 '); 135.35 (Ar1, CH2 Ph); 135.79-136.07 (C6); 150.44 (Ar1, OPh); 151.18 (C2); 164.21-164.28 (C4); 173.42-173.51-173.65 (CO wing)

HPLC: RT = 34.96 and 35.07 min

MS: C 26 H 28 O 8 N 3 P: 542 (MH + 8; 17); 416 (MH + or base; 40); 81 (100).

Exact mass: expected 542.1716; found 542.1712

776 - 5 '- (2,4-Dibromophenyl-N-methylalaninyl) -phosphoramidate from 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Yield = 88%

P 31 (CDCl 3): 3.07 and 3.62 ppm

H 1 (CDCl 3) 1.26 and 1.28 (d, 3H, J = 6.8Hz, CH 3 wing); 1.75 and 1.80 (s, 3H, 5CH3); 2.11 (s, 1 H, NH); 3.64 (s, 3H, OMe); 3.92-4.30 (m, 3H, H5 '+ CHala); 4.98 (m, 1H, H4 '); 5.87 (m, 1H, H2 '); 6.26 (m, 1H, H3 '); 6.96 (m, 1H, H1 '); 7.30-7.60 (m, 4H, Ar + H6); 9.41 (s wide, 1H, NH)

C 13 (CDCl 3): 12.51 (5CH 3); 21.00 (CH 3 wing); 50.24 CHala); 52.80 (OMe); 67.37-67.83 (C5 '); 84.49-84.61 (C4 '); 89.80-89.92 (C1 '); 111.60 (C5); 115.49 (Ar2); 118.26 (Ar4); 122.61-122.89 (Ar6); 127.70 (C2 '); 131.86 (Ar5); 133.06-133.21 (C3 '); 135.64 (Ar3); 135.75-135.88 (C6); 147.01 (Ar1); 151.07 (C2); 164.03 (C4); 173.71-173.82 (COala)

HPLC: RT = 41.17 and 41.30 min

MS: C 20 H 22 O 8 N 3 PBr 2: 622,624,626 (MH + 0; 3,6,3); 496,498,500

(MH + or base; 5,9.5); 81 (100). Exact mass: expected 621.9516; Found 621.9507

779 - 5 '- (2,3,4,5,6-Pentafluorophenyl-N-methylalaninyl) phosphoramidate of 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Yield = 76%

P 31 (CDCl 3) 4.74 and 5.66 ppm

H 1 (CDCl 3) 1.34 and 1.36 (d, 3H, J = 6.7Hz, CH 3 wing); 1.75 and 1.81 (s, 3H, 5CH3); 3.69 (s, 3H, OMe); 3.92-4.40 (m, 4H, H5 '+ CH wing + NH); 4.97 (m, 1H, H4 '); 5.85 (m, 1H, H2 '); 6.29 (m, 1H, H3 '); 6.93 (m, 1H, H1 '); 7.19 (m, 1H, H6); 9.38 (wide s, 1H, NH)

C 13 (CDCl 3) 12.23-12.43 (5CH3); 20.83 (CH 3 wing); 50.22-50.34 (CH to); 52.99 (OMe); 67.75-68.37 (C5 '); 84.42-84.52 (C4 '); 89.87-90.17 (Cl '); 111.75 (C5); 127.69-127.93 (C2 '); 132.86-133.13 (C3 '); 132-143 (m, Ar); 135.74-135.96 (C6); 151.11 (C2); 164.15 (C4); 173.64-173.76 (COala)

Mass (NOBA matrix): C 20 H 19 O 8 N 3 PF 5: 556 (MH + o, 31); 578 (M o + Na, 100)

HPLC: RT = 35.90 min

862 - 5 '- (Phenyl-N-hexyloxyalaninyl) phosphoramidate 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Yield = 88%

P 31 (CDCl 3) 3.99 and 4.60 ppm

H 1 (CDCl 3): 0.94 (m, 3H, C H 3 CH 2); 1.28-1.41 (m, 9H, CH 3 wing + 3XCH 2); 1.65 (m, 2H, CO 2 CH 2 C H 2); 1.90 and 1.93 (s, 3H, 5CH3); 4.00-4.20 (m, 4H, CH wing + NH wing + CO 2 CH 2); 4.37 (m, 2H, H5 '); 5.05 (m, 1H, H4 '); 5.94 (m, 1H, H2 '); 6.38 (m, 1H, H3 '); 7.10 (m, 1H, H1 '); 7.15-7.36 (m, 6H, Ar + H6); 9.48 and 9.51 (s, 1H, NH)

C 13 (CDCl 3) 12.76 (5CH 3); 14.39 (C H 3 CH 2); 21.45 (CH 3 wing); 22.88, 25.82, 28.82 and 31.72 (CH2); 50.63 (CH wing); 66.26 (OCH2); 66.89-67.43 (C5 '); 85.03 (C4 '); 89.97 (Cl '); 111.68-111.83 (C5); 120.55 (Ar ortho); 125.57 (Ar para); 127.86 (C2 '); 130.15 (Ar meta); 133.47-133.70 (C3 '); 136.03-136.31 (C6); 150.72 (Ar ipso); 151.37-151.39 (C2); 164.35-164.42 (C4); 174.02 (CO wing)

Mass (NOBA Matrix): C 25 H 34 O 8 N 3 P: 536 (MH + o, 24); 558 (M o + Na, 37)

863 - 5 '- (Phenyl-N-methoxy-phenylalaninyl) phosphoramidate from 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Yield = 89%

P 31 (CDCl 3): 3.96 and 4.35 ppm

H 1 (CDCl 3): 1.89 (s, 3H, 5CH 2); 3.00 (m, 2H, CH2 Ph); 3.74 (s, 3H, OMe); 3.80-4.28 (m, 4H, CH wing + NH wing + H5 '); 4.94 (m, 1H, H4 '); 5.91 (m, 1H, H2 '); 6.21-6.30 (m, 1H, H3 '); 7.04-7.32 (m, 12H, Ar + H1 '+ H6); 9.35 (s, 1 H, NH)

C 13 (CDCl 3): 12.54 (5CH 3); 40.55 (CH2 Ph); 52.63 (OMe); 55.72-56.01 (CH wing); 66.50-67.10 (C5 '); 84.78 (C4 '); 89.71-89.95 (Cl '); 111.53-111.64 (C5); 120.28 (Ar ortho, OPh); 125.40 (Ar para, OPh); 127.52 (C2 '); 128.86, 129.65 and 129.98 (Ar, CH2 Ph); 129.86-129.92 (Ar meta, OPh); 133.18-133.50 (C3 '); 135.72 (Ar ipso, CH2 Ph); 135.79-136.06 (C6); 150.46 (Ar ipso, OPh); 151.13-151.17 (C2); 164.12-164.18 (C4); 173.00 (Co wing)

Mass (NOBA matrix): C 20 6H 28 O 8 N 3 P: 542 (MH + o, 77); 564 (M o + Na, 29)

864 - 5 '- (Phenyl-N-methoxyleuccinyl) phosphoramidate from 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Yield = 87%

P 31 (CDCl 3) 4.18 and 4.83 ppm

H 1 (CDCl 3) 0.91 (m, 6H, (CH 3) 2 CH); 1.42-1.70 (m, 3H, C H 2 CH (CH 3) 2); 1.91 and 1.93 (s, 3H, 5CH3); 3.73 (s, 3H, OMe); 3.76-3.98 (m, 2H, CH wing + NH wing); 4.28-4.46 (m, 2H, H5 '); 5.08 (m, 1H, H4 '); 5.96 (m, 1H, H2 '); 6.36 (m, 1H, H3 '); 7.09 (m, 1H, H1 '); 7.18-7.35 (m, 6H, Ar + H6); 9.35 (s, 1 H, NH)

C 13 (CDCl 3): 12.76 (5CH 3); 22.23-23.01 ((CH 3) 2 CH); 24.75 (CH (CH 3) 2); 43.86-44.11 (CH 2 CH (CH 3) 2); 52.75 (OMe); 53.42-53.60 (CH wing); 66.92-67.55 (C5 '); 85.62 (C4 '); 89.92-90.19 (Cl '); 111.69-111.83 (C5); 120.37-120.62 (Ar ortho); 125.55-125.58 (Ar para); 127.79 (C2 '); 130.12 (Ar meta); 133.51-133.70 (C3 '); 136.00-136.36 (C6); 151.05 (Ar ipso); 151.38 (C2); 164.39-164.50 (C4); 174.55-174.88 (CO wing)

Mass (NOBA matrix): C 23 H 30 O 8 N 3 P: 508 (MH + o, 62); 530 (M o + Na, 59)

865 - 5 '- (Phenyl-N-methoxivalinyl) phosphoramidate from 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Yield = 86%

P 31 (CDCl 3): 4.85 and 5.40 ppm

H 1 (CDCl 3): 0.92 (m, 6H, (C H 3) 2 CH); 1.82 (m, 3H, CH (CH 3) 2); 1.89 and 1.91 (s, 3H, 5CH3); 3.76 (s, 3H, OMe); 3.82 (m, 2H, CH wing + NH wing); 4.30-4.48 (m, 2H, H5 '); 5.07 (m, 1H, H4 '); 5.96 (m, 1H, H2 '), 6.38 (m, 1H, H3'); 7.10 (m, 1H, H1 '); 7.18-7.35 (m, 6H, Ar + H6); 9.31 (s, 1H, NH)

C 13 (CDCl 3): 12.80 (5CH 3); 17.77-19.24 ((CH 3) 2 CH); 32.43-32.62 (CH (CH 3) 2); 52.67 (OMe); 60.32-60.38 (CH wing); 66.92-67.65 (C5 '); 85.04 (C4 '); 89.98-90.24 (Cl '); 111.76-111.87 (C5); 120.45-120.56 (Ar ortho); 125.54-125.59 (Ar para); 127.81-127.86 (C2 '); 130,13-130.17 (Ar meta); 133.51-133.72 (C3 '); 136.01-136.28 (C6); 150.83 (Ar ipso); 150.87-151.34 (C2); 164.30-164.37 (C4); 173.56-173.65 (CO wing)

Mass: C 22 H 28 O 8 N 3 P: 493.6 (MH <+>, 100)

866 - 5 '- (Phenyl-N-methoxyglycinyl) phosphoramidate from 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Yield = 90%

P 31 (CDCl 3): 4.89 and 5.52 ppm

H 1 (CDCl 3): 1.79 and 1.83 (s, 3H, 5CH3); 3.69 (s, 3H, OMe); 3.70-4.05 (m, 4H, CH 2 NH + CH wing + NH wing); 4.32 (m, 2H, HS '); 4.99 (m, 1H, H4 '); 5.92 (m, 1H, H2 '); 6.38 (m, 1H, H3 '); 6.98 (m, 1H, H1 '); 7.05-7.38 (m, 6H, Ar + H6); 9.44 and 9.46 (s, 1H, NH)

C 13 (CDCl 3): 12.75 (5CH 3); 43.15 ( C H2 NH); 52.94 (OMe); 66.78-67.52 (C5 '); 84.98-85.10 (C4 '); 89.68-90.16 (C1 '); 111.69-111.80 (C5); 120.46-120.59 (Ar ortho); 125.66 (Ar para); 127.66-127.91 (C2 '); 130.22 (Ar meta); 133.48-133.87 (C3 '); 136.11-136.40 (C6); 150.65 (Ar ipso); 151.45 (C2); 164.46 (C4); 171.41-171.51 (CO wing)

Mass (NOBA matrix): C 19 H 22 O 8 N 3 P: 452 (MH + o, 74); 474 (M o + Na, 46)

867 - 5 '- (Phenyl-N-methoxymethioninyl) phosphoramidate from 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Yield = 81%

P 31 (CDCl 3): 4.09 and 4.86 ppm

H 1 (CDCl 3): 1.74 and 1.79 (s, 3H, CH 3 S); 1.94 and 1.97 (s, 3H, 5CH3); 1.80-2.40 (m, 5H, C H C H 2 C H 2 S); 3.72 and 3.74 (s, 3H, OMe); 3.98-4.32 (m, 4H, H5 '+ CH wing + NH wing); 4.96 (m, 1H, H4 '); 5.84 (m, 1H, H2 '); 6.26 (m, 1H, H3 '); 6.96 (m, 1H, 1H '); 7.05-7.25 (m, 6H, Ar + H6); 9.58 (wide s, 1H, NH)

C 13 (CDCl 3): 12.80 (5CH 3); 15.68 (CH 3 S); 29.95 (C H 2 SCH 3); 33.73-33.85 ( C H 2 CH 2 S); 53.06 (OMe); 53.81-54.07 (NH C H); 67.05-67.70 (C5 '); 84.90-85.03 (C4 '); 89.98-90.23 (Cl '); 111.66-111.86 (C5); 120.39-120.66 (Ar ortho); 125.63 (Ar para); 127.81-127.91 (C2 '); 130.18 (Ar Meta); 133.44-133.69 (C3 '); 136.00-136.38 (C6); 150.72-150.80 (Ar ipso); 151.41 (C2); 164.52 (C4); 173.61-173.94 (CO wing)

Mass (NOBA matrix): C 22 H 28 O 8 N 3 PS: 526 (MH + o, 46); 548 (Mº +, 6Na, 21)

868 - 5 '- (2,4-Dibromophenyl-N-benzylalaninyl) -phosphoramidate from 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Yield = 82%

P 31 (CDCl 3): 3.68 and 4.18 ppm

H 1 (CDCl 3): 1.40 and 1.42 (d, 3H, J = 6.7Hz, CH 3 wing); 1.90 and 1.92 (s, 3H, 5CH3); 4.04-4.40 (m, 4H, H5 '+ CHala + NH wing); 4.98 (m, 1 H, H4 '); 5.20 (s, 2H, CH2 Ph); 5.91 (m, 1H, H2 '); 6.27 and 6.35 (m, 1H, H3 '); 7.06 (broad s, 1H, H1 '); 7.30-7.70 (m, 9H, Ar + H6); 9.52 (s, 1 H, NH)

C 13 (CDCl 3): 12.86 (5CH 3); 21.35 (CH 3 wing); 50.68-50.76 (CHala); 67.67-68.03 (C5 '); 67.88 (CH2 Ph); 84.85 (C4 '); 90.10-90.20 (C1 '); 111.88-111.92 (C5); 115.76-115.91 (Ar2); 118.62-118.72 (Ar4); 122.91-123.22 (Ar6); 127.98 (C2 '); 128.75-129.01-129.12 (Ar o, m, p, CH2 Ph); 132.20 (Ar5); 133.38-133.51 (C3 '); 135.48 (Ar ipso, CH2 Ph); 135.96 (Ar3); 136.21 (C6); 147.28 (Ar1); 151.39 (C2); 164.34-164.38 (C4); 173.47-173.62 (COala)

Mass (NOBA matrix) C_26 H_ {26} O8 {3} PBr: 699-700-701 (MH + º, 27-49-29); 721-722-723 (M + Na, 17-21-17)

877 - 5 '- (Phenyl-N-methoxyglycinyl) phosphoramidate from 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Yield = 83%

P 31 (CDCl 3): 3.91 and 4.33 ppm

H 1 (CDCl 3): 1.83 and 1.85 (s, 3H, 5CH 3); 3.01 (m, 2H, CHC H2 Ph); 3.78-4.30 (m, 4H, H5 '+ H NC H ); 4.92 (m, 1H, H4 '); 5.89 (m, 1H, H2 '); 6.18 and 6.27 (m, 1H, H3 '); 7.00-7.40 (m, 17H, Ar + H1 '+ H6); 9.35 (wide s, 1H, NH)

C 13 (CDCl 3): 12.62-12.75 (5CH 3); 40.65-40.73 (CH C H2 Ph); 55.95-56.26 (NHC H ); 66.79-67.27 (C5 '); 67.80 ( C H2 Ph); 84.87-85.05 (C4 '); 89.92-90.14 (Cl '); 111.72-111.82 (C5); 120.45-120.52 (Ar ortho, OPh); 125.60 (Ar para, OPh); 127.73 (C2 '); 129.01-129.07-129.11-129.91-130.15-130.38-135.29-135.85 (Ar, 2xCH2 Ph); 130.21 (Ar meta, OPh); 133.36-133.63 (C3 '); 136.24 (C6); 150.68-150.77 (Ar ipso, OPh); 151.31-151.35 (C2); 164.28-164.34 (C4); 172.48-172.64 (Co ala)

Mass (NOBA matrix): C 32 H 32 O 8 N 3 P: 618 (MH +, 78); 640 (M + +, Na, 52)

878 - 5 '- (Phenyl-N-t-butylphenylalaninyl) phosphoramidate from 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Yield = 79%

P 31 (CDCl 3): 4.27 and 4.50 ppm

H 1 (CDCl 3) 1.40 and 1.41 (s, 9H, tBu); 1.84 and 1.87 (s, 3H, 5CH3); 3.00 (m, 2H, C H2 Ph); 3.76-4.28 (m, 4H, H5 '+ H NC H ); 4.95 (m, 1H, H4 '); 5.86 and 5.91 (m, 1H, H2 '); 6.26 and 6.30 (m, 1H, H3 '); 7.04 (m, 1H, H1 '); 7.12-7.25 (m, 11H, Ar + H6); 9.38 and 9.40 (wide s, 1H, NH)

C 13 (CDCl 3): 12.76-12.79 (5CH 3); 28.31 (( C H 3) 3 C); 40.96-41.04 ( C H2 Ph); 56.31-56.65 (NH C H); 66.79-67.28 (C5 '); 82.90-82.92 ((CH 3) 3 C ); 84.94-85.03 (C4 '); 89.93-90.11 (C1 '); 111.67-111.86 (C5); 120.45 (Ar ortho, OPh); 125.52 (Ar para, OPh); 127.77 (C2 '); 127.88-128.83-128.92-136.02 (Ar, CH2 Ph ); 130.13 (Ar meta, OPh); 133.54-133.60 (C3 '); 136.31 (C6); 150.75-150.84 (Ar ipso, OPh)); 151.36 (C2); 164.32-164.37 (C4); 171.89 (CO wing)

Mass (NOBA matrix): C 29 H 34 O 8 N 3 P: 584 (MH + º, 26); 606 (M + Na, 41)

892 - 5 '- (Phenyl-N-cyclohexyloxyalaninyl) phosphoramidate from 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Yield = 83%

P 31 (CDCl 3): 4.11 and 4.71 ppm

H 1 (CDCl 3): 1.08-1.82 (m, 16H, CH 3 ala + 5CH 3 + cyclohexyl); 3.79-4.14 (m, 2H, CH wing + NH wing); 4.27 (m, 2H, H5 '); 4.69 (m, CH cyclohexyl); 4.96 (m, 1H, H4 '); 5.80 (m, 1 H, H2 '); 6.24 (m, 1H, H3 '); 6.98 (m, 1H, H1 '); 7.04-7.32 (m, 6H, Ar + H6); 9.66 and 9.82 (wide s, 1H, NH).

C 13 (CDCl 3): 12.58 (5CH 3); 21.18-21.32 (CH 3 wing); 23.73-25.40-31.49-31.58 (CH2cyclohexyl); 50.47-50.61 (CH wing); 66.69-67.24 (C5 '); 74.36 ( C H cyclohexyl); 84.87 (C4 '); 89.72-89.92 (C1 '); 111.48-111.63 (C5); 120.26-120.49 (Ar ortho); 125.32-125.37 (Ar para); 127.59-127.73 (C2 '); 129.91-129.98 (Ar meta); 133.30-133.51 (C3 '); 135.89-136.16 (C6); 150.53 (Ar ipso); 150.67-151.31 (C2); 164.36-164.41 (C4); 173.23 (CO wing).

Mass (NOBA matrix): C 25 H 32 O 8 N 3 P: 534 (MH +, 56); 556 (M + Na, 42)

893 - 5 '- (Phenyl-N-butyloxyalaninyl) phosphoramidate from 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Yield = 79%

P 31 (CDCl 3): 4.17 and 4.67 ppm.

H 1 (CDCl 3): 1.34 (m, 3H, CH 3 wing); 1.46 (m, 9H, CH 3 tBu); 1.87 (d, 3H, 5CH3); 3.82-4.06 (m, 2H, H5 '); 4.29-4.49 (m, 2H, CH wing + NH wing); 5.05 (m, 1H, H4 '); 5.91 (m, 1H, H2 '); 6.35 (m, 1H, H3 '); 7.06 (m, 1H, H1 '); 7.15-7.40 (m, 6H, Ar + H6); 9.60 (broad s, 1H, NH).

C 13 (CDCl 3): 12.54 (5CH 3); 21.19-21.35 (CH 3 wing); 28.07 (C (CH 3) 3); 50.80-50.89 (CH to); 66.60-67.18 (C5 '); 82.41-82.45  (C (Me) 3); 84.82 (C4 '); 89.67-89.87 (C1 '); 111.44-111.60 (C5); 120.22-120.41 (Ar ortho); 125.28-125.31 (Ar para); 127.54-127.65 (C2 '); 129.88-129.94 (Ar meta); 133.33-133.47 (C3 '); 135.84-136.10 (C6); 150.51 (Ar ipso); 150.65-151.20 (C4); 164.19-164.23 (C2); 172.78-172.93 (CO wing).

Mass (NOBA matrix): C 23 H 30 O 8 N 3 P: 508 (MH + 82, 82); 530 (m <+> Na, 48).

5 '- (Phenylmethoxy-B-alaninyl) phosphate from 2 ', 3'-dideoxy-2', 3'-dihydrotimidine

Cf 1197

Yield = 64%

P 31 (CDCl 3): 6.44, 6.70 (1: 3)

H 1 (CDCl 3): 1.87 ° (s, 3H, 5-CH 3), 2.42 (t, 2H, CH 2 wing), 3.22 ° (m, 2H, CH2 ala), 3.62 (s, 3H, 0CH3), 4.09 (m, 1H, H4 '), 4.18-4.39 (m, 2H, H5 '), 4.97 (broad s, 1H, NH wing), 5.88 ° (m, 1H, H2 '), 6.32 ° (m, 1H, H3'), 6.99 (m, 1H, H1 '), 7.08-7.38 (m, 5H, Ph and H6), 10.01 (wide s, 1H, base NH)

C 13 (CDCl 3): 14.52 (5-CH 3), 37.80 ° (CH 2 wing), 39.28 ° (CH 2 wing), 53.91 ° (0CH 3), 68.57 ° (d, J = 3.92 Hz, C5 '), 86.90 (d, J = 8.38 Hz, C4 '), 91.68 ° (C1'), 113.40 ° (C5), 122.34 (d, J = 4.68 Hz, ortho-Ph), 127.23 (C2 '), 129.55 ° (para-Ph), 131.81º (meta-Ph), 135.45º (C6), 137.99º (C3 '), 152.60º (d, J = 5.96 Hz, ipso-Ph), 153.44 (C2), 166.58 (C4), 174.55º (COO)

Mass (NOBA matrix): C 20 H 24 N 3 O 8 P 126 (thymine +, 5), 127 (thymineH <+>, 4), 242 (C 10 H 13 PO 4 N +, 9), 243 (C 10 H 14 PO 4 N +, 3), 465 (M +, 4), 466 (MH <+>, 8), 467 (MHNa <+>, 20), 168 (MHNa <+>, O <13, 5), 187 (MNa +, 3), 188 (MHNa +, 97), 189 (MHNa +, C 13, twenty-one)

High Resolution MS: found 466,1379 (MH +), C 20 H 25 N 3 O 8 P requires 466.1379

HPLC: RT = 22.81, 23.27 mins (1: 1)

5 '- (Phenylmethoxy-? -Aminobutyryl) phosphate from 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Cf 1198

Yield = 65%

P 31 (CDCl 3): 6.11, 6.66 (1: 2)

H 1 (CDCl 3): 1.78 (m, 2H, CH 2 GABA), 1.85º (s, 3H, 5-CH3), 2.35 (t, 2H, J = 6.95 Hz, CH 2 GABA), 2.97 ° (m, 2H, CH 2 GABA), 3.68 (s, 3H, OCH 3), 3.93 ° (m, 1H, H4 '), 4.28 ° (m, 1H, H5'), 4.35 ° (m, 1H, H5 '), 5.02 (broad s, 1H, NH GABA), 5.82 ° (m, 1H, H2'), 6.31 (m, 1H, H3 '), 6.98 (m, 1H, H1'), 7.11-7.37 (m, 6H, Ph and H6), 9.91 (wide s, 1H, NH base)

C 13 (CDCl 3): 12.64 (5-CH 3), 26.72 ° (CH 2 GABA), 32.25 ° (CH 2 GABA), 40.98 ° (CH 2 GABA), 51.94 (OCH 3), 66.93 ° (C5 '), 85.11 (d, J = 8.30 Hz, C4'), 111.40 (C5), 120.46 ° (d, J = 4.83 Hz, ortho-PH), 125.24 (C2 '), 127.59 ° (para-Ph), 129.88º (meta-Ph), 133.68 (C6), 136.28º (C3 '), 150.86º (d, J = 6.45 Hz, ipso-Ph), 151.61 (C2), 164.80 (04), 173.86º (COO)

Mass (NOBA matrix): C 21 H 26 N 3 O 8 P: 127 (thymine H +, 28), 479 (M +, 3), 480 (MH +, 59), 481 (MH +, C 13, 17), 501 (MNa +, 3), 502 (MHNa +, 59), 503 (MHNa +, C 13, 16)

MS High Resolution: found 480,1486 (MH +), C 21 H 27 N 3 O 8 P requires 480.1536

HPLC: RT 23.90, 24.33 mins (1: 1)

5 '- (Phenylmethoxy-2-aminoisobutyryl) phosphate from 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Cf 1200

Yield = 36%

P 31 (CDCl 3): 2.38, 3.05 (3: 1)

H 1 (CDCl 3): 1.53 ° (s, 6H, CMe 2), 1.91 ° (s, 3H, 5-CH 3), 3.71 (s, 3H, OCH 3), 4.31 (m, 2H, H5 '), 4.23-4.41 (m, 3H, H4' and H5 '), 5.03 (broad s, 1H, P-NH) 5.89 ° (m, 1H, H2 '), 6.28 ° (m, 1H, H3 '), 6.99-7.31 (m, 7H, Ph, HO and H1'), 9.09 (s wide, 1H, NH base)

C 13 (CDCl 3): 14.27 (5-CH 3), 28.74 ° (C Me 2), 54.81 ° (OCH 3), 58.88 ( C Me 2), 69.03 ° (d, C ', J = 5.58 Hz), 86.57 ° (d, J = 7.88 Hz, C4'), 91.51 ° (C1 '), 113 , 24º (C5), 122.01º (d, J = 4.95 Hz, ortho-Ph), 126.88 (C2 '), 129.25º (para-Ph), 131.57º (meta-Ph), 135.19º (C6), 137.68º (C3 '), 152.52º (d, J = 3.09 Hz, ortho-Ph), 153.05 (C2), 166.12 (C4), 177.69º (COO)

MS (NOBA matrix): 354 ((MH-thymine) +, base peak), 479 (M +, 3), 480 (MH +, 64), 481 (MH +, C 13, 17), 482 (MH +, 2 X C 13, 3), 502 (MNa +, 92), 503 (MHNa +, 24)

MS High Resolution: found 480,1503 (MH +), C 21 H 27 N 3 O 8 P requires 480.1536

HPLC: RT 24.79, 25.29 mins (1: 1)

5 '- (Phenylmethoxy-6-aminocaproyl) phosphate from 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Cf 1199

Yield = 80%

P 31 (CDCl 3): 6.90, 6.30 (1: 1)

H 1 (CDCl 3): 1.28 (s, 2H, CH 2 caproyl), 1.45 (m, 2H, CH2 caproyl), 1.58 (m, 2H, CH2 caproyl), 1.82 ° (s, 3H, 5-CH 3), 2.28 (m, 2H, CH2, caproyl), 2.87 (m, 2H, CH2caproyl), 3.65 (s, 3H, OCH 3), 3.81 (m, 1H, H4 '), 4.25 (m, 2H, H5'), 4.95 (wide s, 1H, NH caproyl), 5.86 ° (m, 1H, H2 '), 6.31 ° (m, 1H, H3'), 6.98 (m, 1H, H1 '), 7.04-7.38 ° (m, 6H, Ph and H6), 10.12 (wide s, 1H, NH base)

C 13 (CDCl 3): 13.47 ° (5-CH 3), 25.43 ° (CH 2 caproyl), 27.04 ° (CH 2 caproyl), 32.15 ° (CH 2 caproyl), 34.85 (CH 2) caproyl), 42.30 ° (CH 2 caproyl), 52.61 (OCH 3), 67.92 ° (C5 '), 85.80 (d, J = 8.22 Hz), 90.68º (C4'), 112.25º (C5), 121.17º (d, J = 4.58 Hz, ortho-Ph), 125.99 (C2 '), 128.40º (para-Ph), 130.77 (meta-Ph), 134.38º (C6), 137.09º (C3 '), 151.69º (d, J = 3.23 Hz, ortho-Ph), 152.26 (C2 '), 165.36 (C4'), 175.07 (COO)

MS (Cl matrix): 127 (thymineH +, 42), 508 (MH <+>, 18), 509 (MH <+>, C <13>, 5)

MS High Resolution: Found 508.1850 (MH +), C 23 H 31 N 3 O 8 P requires 508.1849

HPLC: RT 26.33 mins

Ammonium salt 5 '- (β-alaninyl) phosphate 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Cf 1216

Yield = 62%

P 31 (D 2 O): 8.84

H 1 (D 2 O): 1.73 (3H, s, 5-CH 3), 2.18 (2H, m, wing CH 2), 2.65 (m, 2H, wing CH2), 3.79 (2m, H, H5 '), 4.95 (m, 1H, H4'), 5.76 (m, 1H, H2 '), 6.35 (m, 1H, H3'), 6.82 (m, 1H, H1 '), 7.47 (s, 1H, H6)

C 13 (D 2 O): 11.81 (5-CH 3), 38.51 (wing CH 2), 39.45 (d, wing CH2, J = 6.64 Hz), 65.41 (d, C5 ', J = 4.91 Hz), 86.40 (d, J = 9.20 Hz, C4 '), 90.20 (C1'), 111.07 (C5), 125.40 (C2 '), 134.66 (C3'), 138.54 (C6), 152.53 (C2), 167.00 (C4), 181.04 (COO)

HPLC: RT = 32.74 mins.

Ammonium salt 5 '- (γ-aminobutyryl) phosphate of 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Cf 1224

Yield = 54%

P 31 (D 2 O): 10.03

H 1 (D 2 O): 1.47 (m, 2H, CABA CH 2), 1.72 (s, 3H, 5-CH 3), 1.98 (m, 2H, GABA CH2), 2.48 (m, 2H, GABA CH2), 3.72 (m, 2H, H5 '), 4.91 (m, 1H, H4 '), 5.72 (m, 1H, H2'), 6.26 (m, 1H, H3 '), 6.72 (m, 1H, H1'), 7.45 (s, 1H, H6 ').

C 13 (D 2 O): 11.79 (5-CH 3), 27.99 (d, J = 7.25 Hz, GABA CH 2), 34.47 (GABA CH2), 41.17 (GABA CH2), 65.35 (d, J = 4.68 Hz, C5 '), 86.38 (d, J = 9.36 Hz, C4'), 90.27 (C1 '), 111.47 (C5'), 125.29 (C2 '), 134.70 (C3'), 138.68 (C6), 152.47 (C2), 166.95 (C4), 182.32 (COO)

5 '- (caproyl) phosphate ammonium salt 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Cf 1217

Yield = 49%

P 31 (D 2 O): 10.18

H 1 (D 2 O): 1.01 (m, 2H, caproyl CH2), 1.21 (m, 2H, caproyl CH2), 1.32 (m, 2H, caproyl CH2), 1.78 (s, 3H, 5-CH3), 2.05 (m, 2H, caproyl CH2), 2.58 (m, 2H, caproyl CH2), 3.78 (m, 2H, H5 '), 4.99 (s, 1H, H4'), 6.32 (m, 1H, H3 '), 6.82 (m, 1H, H2'), 7.51 (s, 1H, H6)

C 13 (D 2 O): 11.84 (5-CH 3), 25.66 (caproyl CH 2), 26.46 (caproyl CH2), 31.10 (d, J = 6.82 Hz, caproyl CH2), 37.06 (caproyl CH2), 41.47 (caproyl CH2), 65.37 (d, J = 4.83 Hz, C5 '), 86.45 (d, J = 9.74 Hz, C4'), 90.29 (C1 '), 111.43 (C5), 125.27 (C2 '), 134.80 (C3'), 138.89 (C6), 152.48 (C2), 166.94 (C4), 183.15 (COO).

       \ newpage
    

5 '- (Phenylmethoxysarcosinyl phosphate) of 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Cf 1098

Yield = 65%

P 31 (CDCl 3): 6.80, 7.36 ppm

H 1 (CDCl 3): 1.72 (s, 3H, 5CH 3); 2.64, 2.67 (s, 3H, NCH3); 3.62 (s, 3H, OCH3); 3.40-4.10 (m, 2H, CH2); 4.20-4.50 (m, 2H, H5 '); 4.97 (wide s, 1H, H4 '), 5.80-5.90 (m, 1H, H2 '); 6.30-6.40 (m, 1H, H3 '); 6.97 (broad s, 1H, H1 '); 7.00-7.30 (m, 6H, Ar + H6); 9.59 (wide s, 1H, NH)

C 13 (CDCl 3): 12.35 (5CH 3); 34.55-34.60-34.65 (NCH3); 50.67-50.78-50.87 (CH2); 52.10-52.13 (OCH3); 62.27-66.77-66.82 C5 '); 84.71-84.84 (C4 '); 89.52-89.82 (C1 '); 111.16-111.33 (C5); 120-150 (m, Ar); 127.17-127.40 (C2 '); 133.25-133.62 (C3 '); 135.73-136.11 (C6); 150.85-150.90 (C2); 163.84-163.87 (C4); 170.57-170.60-170.84
( C OOCH_ {3})

Mass: C 20 H 24 O 8 N 3 P: 488 ((M + Na) +, 100); 466 ((M + H) +, 5)

HPLC: RT = 25.17 and 25.59 min

5 '- (Phenylethoxysarcosinyl phosphate) of 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Cf 1133

Yield = 65%

P 31 (CDCl 3): 0.87, 7.41 ppm

H 1 (CDCl 3): 1.18-1.24 (m, 2H, CH 3 C H 2); 1.80 (s, 3H, 5CH3); 2.68, 2.71 (s, 3H, NCH3); 3.46-3.65 (m, 2H, NCH2); 3.91-4.45 (m, 2H, H5 '); 4.11, 4.13 (s, 3H, CH 2 C H 3); 5.00 (broad s, 1H, H4 '); 5.82-5.88 (m, 1H, H2 '); 6.33-6.37 (m, 1H, H3 '); 7.00 (broad s, 1H, H1 '); 7.10-7.50 (m, 6H, Ar + H6); 8.75 (wide s, 1H, NH)

C 13 (CDCl 3): 12.86-12.89 (5CH 3); 14.69 (CH 2 C H 3); 35.06-35.11 (NCH3); 51.35-51.43-51.51 (NCH2); 61.77 ( C H2
CH 8); 66.77-67.27-67.33 (C5 '); 85.26-85.36 (C4 '); 90.01-90.31 (C1 '); 111.69-111.86 (C5); 120-151 (m, Ar); 127.73-127.96 (C2 '); 133.73-134.10 (C3 '); 136.27-136.64 (C6); 151.61 (C2); 164.70 (C4); 170.62-170.66-170.85 ( C OOCH 3)

Mass: C 21 H 26 O 8 N 3 P: 502 ((M + Na) +, 100); 480 ((M + H) +, 5)

HPLC: RT = 25.84 and 26.65 min

5 '- (Methionyl phosphate) of 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Cf 1156

Yield = 52%

P 31 (CDCl 3): 7.77 ppm

H 1 (CDCl 3): 1.75-1.85 (m, 2H, CH 2 S); 1.90 (s, 3H, SCH 3); 2.01, 2.10 (s, 3H, 5CH3); 2.30-2.50 (m, 2H, CH2CH2S); 3.45-3.60 (m, 1 H C H NH); 3.94 (s, 2H, H5 '); 5.05 (broad s, 1H, H4 '); 5.90-6.00 (m, 1H, H2 '); 6.40-6.50 (m, 1H, H3 '); 6.93 (broad s, 1H, H1 '); 7.68 (s, 1H, H6)

C 13 (CDCl 3): 11.91 (5CH 3); 14.46 (SCH 3); 29.58 (CH 3 S C H 2 CH 2); 34.69 (SCH 2 CH 2); 56.42 (CHNH); 65.07-65.13 (C5 '); 86.39-86.52 (C4 '); 90.14 (Cl '); 111.70 (C5); 125.48 (C2 '); 134.77 (C3 '); 138.91 (C6); 152.61 (C2); 167.18 (C4); 180.84 (COOH)

Mass: C 15 H 22 O 8 N 3 PS: 434 ((M-1), 100); 435 ((M), 15)

HPLC: RT = 31.38 min

5 '- (Glycinyl phosphate) of 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Cf 1163

Yield = 75%

P 31 (CDCl 3): 11.72 ppm

H 1 (CDCl 3): 1.83 (s, 3H, 5CH 3); 3.29 (d, CH2, J = 7.9Hz); 3.85-3.92 (m, 2H, H5 '); 5.00 (s, 1H, H4 '); 5.85-5.88 (m, 1H, H2 '); 6.38-6.41 (m, 1H, H3 '), 6.88-6.90 (s wide, 1H H1 '); 7.54 (s, 1H, H6)

C 13 (CDCl 3): 19.09 (5CH 3); 52.24 (CH2); 72.74-72.81 (C5 '); 93.61-93.73 (C4 '); 97.57 (C1 '); 119.08 (C5); 132.80 (C2 '); 141.89 (C3 '); 145.74 (C6); 159.87 (C2); 174.34 (C4); 186.03-186.15 (COOH)

Mass: C_ {12} H_ {16} O_ {8} N_ {3} P: 360 ((M-1), 100); 361 ((M), 15)

HPLC: RT = 32.57 min

5 '- (Phenylmethoxyisoleuccinyl phosphate) of 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Cf 1186

Yield = 82%

P 31 (CDCl 3): 4.59, 5.16 ppm

H 1 (CDCl 3): 0.91-0.99 (m, 6H, CH 3 + CH 3); 1.09-1.26 (C H CH 3); 1.28-1.56 (m, 2H, CH2); 1.92, 1.97 (s, 3H, 5CH3); 3.60-3.77 (m, 1H, C H NH); 3.77 (s, 3H, OCH3); 3.88-3.99 (m, 1H, N H CH); 4.30-4.52 (m, 2H, H5 '); 5.11-5.13 (m, 1H, H4 '); 5.95-6.00 (m, 1H, H2 '); 6.35-6.45 (m, 1H, H3 '); 7.10-7.13 (m, 1H, H1 '); 7.16-7.45 (m, 6H, Ar + H6); 8.68 (broad s, 1H, NH)

C 13 (CDCl 3): 11.90-11.92 (CH 2 CH 3); 12.76-12.81 (5CH3); 15.64 (CH C H 3); 25.06-25.14 (CH 2 C HCH 3); 39.39-39.47-39.52-39.60 (CH2); 52.61 (OCH3); 59.38-59.54 (NHCH); 66.94-67.58-67.65 (C5 '); 84.91-85.04-85.16 (C4 '); 89.94-90.21 (C1 '); 111.75-111.87 (C5 '); 120-151 (m Ar); 127.82-127.87 (C2 '); 133.49-133.69 (C3 '); 135.99-136.28 (C6); 151.37 (C2); 164.40 (C4); 173.53-173.59-173.64 ( C OOCH 3)

Mass: C 23 H 30 O 8 N 3 P 529.91 ((M + Na) +, 100)

HPLC: RT = 30.52 and 31.14 min

5 '- (Phenylalanyl phosphate) of 2 ', 3-dideoxy-2', 3'-dideshydrotimidine

Cf 1187

Yield = 68%

P 31 (CDCl 3): 7.58 ppm

H 1 (CDCl 3): 1.70 (s, 3H, 5CH 3); 2.64-2.80 (m, 2H, C H2 Ph); 3.57-3.64 (m, 1H, CHNH); 3.68-3.70 (m, 2H, H5 '); 4.85 (s, 1H, H4 '); 5.73-5.75 (m, 1H, H2 '); 6.26-6.29 (m, 1H, H3 '); 6.74-6.75 (m, 1H, H1 '); 7.02-7.28 (m, 5H, CH2 Ph ); 7.44 (s, 1H, H6)

C 13 (CDCl 3): 11.88 (5CH 3); 40.92-40.97 (CH2 ala); 58.27 (CH wing); 65.22-65.28 (C5 '); 86.36-86.49 (C4 '); 90.22 (C1 '); 111.63 (C5); 125.38 (C2 '); 126-129 (m, Ar); 134.74 (C3 '); 138.31-138.48 (C6); 152.40 (C2); 166.81 (C4); 180.87-180.96 (COOH)

Mass: C 19 H 22 O 8 N 3 P: 450 ((M-1), 100); 451 ((M, 20)

HPLC: RT = 32.11 min

5 '- (Valinylphosphate) of 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Cf 1190

Yield = 67%

P 31 (CDCl 3): 8.35 ppm

H 1 (CDCl 3): 0.72 (t, 6H, (C H 3) 2 CH, J = 7.3 Hz); 1.62-1.73 (m, 1H, (CH 3) 2 CH); 1.77 (s, 3H, 5CH3); 3.12 (dd, 1H, NHCS, J = 5.6 Hz and 9.4 Hz); 3.80 (dd, 2H, H5 ', J = 3.5 Hz and 4.4 Hz); 4.92 (s, 1H, H4 '); 5.76-5.78 (m, 1H, H2 '); 6.31-6.35 (m, 1H, H3 '); 6.79-6.81 (m, 1H, H1 '); 7.53 (s, 1H, H6)

C 13 (CDCl 3): 11.84 (5CH 3); 17.95-18.84 (( C H 3) 2 CH); 32.30-32.38 ((CH 3) 2 C H); 62.43 (CHNH); 65.18-65.24 (C5 '); 86.43-86.58 (C4 '); 90.25 (C1 '); 111.65 (C5); 125.20 (C2 '); 134.90 (C3 '); 138.73 (C6); 152.52 (C2); 167.05 (C4); 181.27-181.31 (COOH)

Mass: C 15 H 22 O 8 N 3 P: 402 ((M-1); 100); 403 ((M) -, 30)

HPLC: RT = 31.90 min

5 '- (Leucinylphosphate) of 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Cf 1192

Yield = 83%

P 31 (CDCl 3): 7.98 ppm

H 1 (CDCl 3): 0.71 (d, 6H, (C H 3) 2 CH, J = 6.5 Hz); 1.22-1.34 (m, 2H, CH2); 1.34-1.71 (m, 1H, (CH 3) 2 C H ); 1.80 (s, 3H, 5CH3); 3.30-3.38 (m, 1H, C H NH); 3.82-3.85 (m, 2H, H5 '); 4.95 (s, 1H, H4 '); 5.80-5.82 (m, 1H, H2 '); 6.35-6.37 (m, 1H, H3 '); 6.81-6.82 (m, 1H, H1 '); 7.58 (s, 1H, H6)

C 13 (CDCl 3): 12.53 (5CH 3); 22.88-22.99 (( C H 3) 2 CH); 25.28 (CH2); 45.27-45.34 ((CH 3) 2 C H); 56.38 (CHNH); 65.74-65.81 (C5 '); 87.12-87.25 (C4 '); 90.89 (C1 '); 112.30 (C5); 125.99 (C2 '); 135.49 (C3 '); 139.44 (C6); 153.12 (C2); 167.70 (C4); 183.36-182.42 (COOH)

Mass: C 16 H 24 O 8 N 3 P: 416 ((M-1), 100); 417 ((M -, 20)

HPLC: RT = 35.02 min

5 '- (Phenylmethoxyalaninyl phosphate) of 2 ', 3-dideoxy-2', 3'-dideshydrotimidine [diastereoisomer Quick]

Cf 1193

P 31 (CDCl 3): 4.51 ppm

H 1 (CDCl 3): 1.25-1.40 (m, 3H, CHC H 3); 1.86-1.90 (m, 3H, 5CH3); 3.74-3.90 (m, 4H, OCH3 + CH wing); 4.37-4.47 (m, 2H, H5 '); 5.08 (broad s, 1H, H4 '); 5.91-5.93 (m, 1H, H2 '); 6.38-6.41 (m, 1H, H3 '); 7.07-7.09 (m, 1H, H1 '); 7.20-7.39 (m, 6H, Ar + H6); 9.04 (broad s, 1H, NH)

C 13 (CDCl 3): 10.85 (5CH 3); 19.38-19.45 (CH C H 3); 48.71 ( C HCH 3); 51.14 (OCH3); 64.91-64.97 (C5 '); 83.11-83.22 (C4 '); 88.03 (C1 '); 109.77 (C5); 118-149 (m, Ar); 125.84 (C2 '); 131.88 (C3 '); 134.44 (C6); 149.34 (C2); 162.35 (C4); 172.53-172.62 (CO wing)

5 '- (Phenylprolinylphosphate) of 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Cf 1194

Yield = 41%

P 31 (CDCl 3): 5.27 ppm

H 1 (CDCl 3): 1.55 (s, 3H, 5CH 3); 1.56-2.15 (m, 4H, CHC H2 CH2); 3.10-3.30 (m, 2H, NCH2); 3.90-4.00 (m, 1H, NCH); 4.20-4.50 (m, 2H, H5 '); 5.11 (s, 1H, H4 '); 5.89-5.91 (m, 1H, H2 '); 6.41-6.44 (m, 1H, H3 '); 6.76-6.78 (m, 1H, H1 '); 6.99-7.40 (m, 6H, Ar + H6)

C 13 (CDCl 3): 11.84 (5CH 3); 25.44-25.56 ( C H 2 CH 2 N); 31.94-32.06 ( C H2 CHN); 47.40-47.46 (NCH2); 63.31 (CHN); 67.14-67.21 (C5 '); 85.56-85.68 (C4 '); 90.69 (C1 '); 111.00 (C5), 120-150 (m, Ar), 125.07 (C2 '), 134.13 (C3'), 138.26 (C6), 152.67 (C2), 166.64 ( C4), 181.32 (COOH)

Mass: C 21 H 24 O 8 N 3 P: 476 ((M-1), 100); 477 ((M) -, 25)

HPLC: RT = 34.16 min

1001-5 '- (Phenylmethoxyalaninyl phosphoramidate of 2 ', 3'-dideoxy-2', 3 ' dideshydroadenosine

Yield = 67%

H 1 (dmso-d6): 8.14 (1H, s, H8), 8.06 (1H, d, H2), 7.07-7.40 (7H, m, Phe-H & NH2), 6.93 (1H, s, H1 '), 6.47 (1H, 2d, H3 '), 6.21 (1H, d, H3'), 5.96 (1H, m, NH), 5.11 (1H, m, H4 '), 4.10 (2H, m, H5 '), 3.5-4.83 (1H, 2m, CH wing), 3.52 (3H, d, MeO), 1.08 (3H, 2d, CH 3 ala)

P 31 (dmso-d6): 4.92, 4.78.

C 13 (dmso-d6): 172,909-172,815 (CO wing), 154,663 (C-2), 152,238 (C-6), 149,524-149,442 (Ar-ipso), 148,782 (C-4), 138,006-137,907 (C-8), 132,286-132,205 (C-2 '), 128,621 (Ar-meta), 125,384-125,210 (Ar para), 123,928 (C-3 '), 119,067-119.00 (Ar ortho), 118,508 (C-5), 87,311-87,060 (C-1 '), 84,485-84,368 (C-4 '), 66,093-65,324 (C-5 '), 51,477-51,429 (OMe), 49,109-48,989 (C-H wing), 19,903-19,585 (CH 3, wing).

Mass. Calculated MH +: 475, l49. Found: 475,151

1094-5 '- (Phenylbenzylalaninyl) phosphoramidate of 2 ', 3'-dideoxy-2', 3'-dideshydroadenosine

Yield = 65%

H 1 (CDCl 3): 8.32 (1H, broad s, H-8), 7.99 (1H, wide s, H-2), 7.21 (11H, m, Ar-H & H1 '), 6.34 (1H, m, H3'), 6.07 (1H, m, H2 '), 5.81 (2H, 2s wide, NH2), 5.08 (3H, 2s wide, Bz-CH2 & H4 '), 4.05 (4H, m, NH, CH, H5'), 1.24 (3H, 2d, methyl wing, J = 6.9 Hz).

P 31 (CDCl 3): 4.21, 3.98

C 13 (CDCl 3): 173,700 & 173,601 (O-C = o), 156,005 (C-2), 153,728 (C-6), 150,952 & 150,870 (Ar), 150,322 & 150,280 (C-4), 139,484 & 139,368 (C-8), 135,672 (Ar), 133,733 & 133,654 (C-2 '), 130,066 (Ar), 129,041, 128,895, 128,635 & 128,601 (Ar), 126,751 & 126,598 (C-3 '), 125,375 (Ar), 120,529, 120,463, 120,399, 120,119 & 120,051 (C-5 & Ar), 88,702 & 88,476 (C-1 '), 85,907, 85,476, 85,791 & 85,736 (C-4 '), 67,632, 67,475 & 67,403 (C-5 'and Bz-CH2), 66,805 & 66,745 (C-5 '), 50,677 & 50,542 (Wing C-H), 21,399, 21,335, 21,083 & 21,019 (methyl To).

Mass: Calculated MH <+>: 551,181. Found: 551,179.

1168-5'-Alaninylphosphoramidate of 2 ', 3'-dideoxy-2', 3'-dideshydroadenosine

Yield = 69%

rmn H 1 (D 2 O): 8.09 (1H, s, H8), 7.88 (1H, s, H2), 6.81 (1H, s, H1 '), 6.33 (1H, d, H3'), 6.02 (1H, d, H3 '), 5.01 (1H, m, H4'), 4.73 (2H, m, H5 '), 3.5-4.83 (1H, 2m, CH wing), 0.89 (3H, 2d, CH 3 wing)

P 31 (D 2 O): 8.34.

C 13 (D 2 O): 183.055 (CO wing), 155.549 (C-2), 152,745 (C-6), 148,643 (C-3), 140,928 (C-8), 134,730 (C-2 '), 124,709 (C-3'), 118,527 (C-5), 88,299 (C-1 '), 87,199 & 87,073 (C-4 '), 65,215-65,149 (C-5 '), 52,564 (Alal C-H), 21,435-21,381 (Ala CH 3).

1196-5 '- (Phenyldimethoxy-glutaminyl phosphoramidate of 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

Yield 33%

P 31 (CDCl 3): 4.14, 4.76

H 1 (CDCl 3): 1.81, 1.85 (5CH 3); 1.91-2.18 (m, 2H, Gln); 2.24-2.36 (m, 2H, CH2 Gln); 3.64 (s, 3H, NMe); 3.69 (s, 3H, OMe); 3.92-4.21 (m, 2H, H5 '); 4.23-4.42 (m, 2H, CH Gln, NH Gln); 5.00 (m, 1H, H4 '); 5.91 (m, 1H, H2 '); 6.31 (m, 1H, H3 '); 7.01 (m, 1H, H1 '), 7.03-7.34 (m, 6H, Ph, H6); 9.49 (s, 1 H, NH)

C 13 (CDCl 3): 12.32-12.36 (5CH3); 29.01-29.42 (CH2 Gln); 29.46 (NMe); 51.81 (CH Gln); 52.65 (OMe); 53.65-53.92 (CH2 Gln); 66.63-67.33 (C5 '); 84.48-84.71 (C4 '); 89.57-89.83 (C1 '); 111.29-111.44 (C5); 119.98-120.22 (Ph); 125.21-125.26 (Ph); 127.39-127.50 (C2 '); 129.74-129.78 (Ph); 133.00-133.25 (C3 '); 135.60-135.90 (C6); 150.98 (C2); 164.00-164.09 (C4); 172.96-173.23 (CO, CON)

Mass (ES): H_ {23} H_ {29} N_ {4} P: 536 (M +, 100); 537 (MH +, 32)

1214 - 5 '- (Phenyldimethoxy-asparraginyl) phosphoramidate from 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

75% yield

P 31 (CDCl 3): 1.15, 2.20

H 1 (CDCl 3): 1.81, 1.86 (s, 3H, 5CH3); 2.49-2.92 (m, 2H, CH2 Gln); 3.64 (s, 3H, NMe); 3.72 (s, 3H, OMe); 4.04-4.26 (m, 2H, H5 '); 4.28-4.43 (m, 2H, CH Asn, NH Asn); 5.05 (m, 1H, H4 '); 5.89 (m, 1H, H2 '); 6.31 (m, 1H, H3 '); 7.01 (m, 1H, H1 '); 7.14-7.33 (m, 6H, Ph, H6); 8.46 (s, 1 H, NH)

C 13 (CDCl 3): 12.28 (5CH 3); 51.01 (CH Asn); 52.09 (OMe); 52.94 (CH2 Asn); 84.75 (C4 '); 89.60 (C1 '); 111.30 (C5); 125-130 (Ph); 127.32-127.48 (C2 '); 133.10-133.41 (C3 '); 135.94 (C6)

Mass (ES): C_22 H_ {27} N4 {9} P: 522 (M +, 100); 523 (MH <+>, 31)

1215 - 5 '- (Phenylmethoxy-triptophanyl) phosphoramidate of 2 ', 3'-dideoxy-2', 3'-dideshydrotimidine

100% yield

P 31 (CDCl 3): 4.15, 4.57

H 1 (CDCl 3): 1.74 (s, 3H, 5CH 3); 3.16 (m, 2H, CH2 Trp); 3.60 (s, 3H, OMe); 3.75-4.05 (m, 2H, H5 '); 4.10-4.33 (m, 2H, CH Trp NH Trp); 4.84 (m, 1H, H4 '); 5.79 (m, 1H, H2 '); 6.15 (m, 1H, H3 '); 6.86 (m, 1H, H1 '); 6.91 (m, 1H, H6); 7.00-7.49 (m, 10H, Ar); 8.45 (s, 1 H, NH Trp); 9.14 (s, 1H, NH)

C 13 (CDCl 3): 14.75 (5CH 3); 32.46 (CH 2 Trp); 54.91 (CH Trp); 57.53-57.61 (OMe); 69 (C5 '); 87.06 (C4 '); 92.03-92.25 (C1 '); 111.63 (C5); 127.60 (C2 '); 135.45-135.83 (C3 '); 138.11-138.62 (C6); 152.78-153.41 (C2); 166.28-166.40 (C4); 175.85 (CO)

Mass (ES): C_ {28} H_ {28} N_ {4} P: 579 (M +, 100); 580 (M +, 43)

In Vitro Test

The cells were infected with HIV-1 as described previously [Balzarini et al ., AIDS (1991), 5 , 21-28]. In summary, 5 x 10 5 cells per milliliter were infected with HIV-1 or HIV-2 at 100 DICC 50 (50% cell culture infective dose) per milliliter of cell suspension. Then 100 µl of the infected cell suspension was transferred to wells of a microtiter plate and mixed with 100 µl of the appropriate dilutions of the test compounds. After 4 days, giant cell formation was recorded microscopically in HIV-infected cell cultures [EMF], and after 5 days the number of viable cells was determined by trypan blue staining of HIV-infected cell cultures [MT4] The 50% effective concentration (EC50) and 50% cytotoxic concentration (CC50) were defined as the compound concentrations required to reduce by 50% the number of giant cells or viable cells in the cell cultures infected by the virus or simulated infected, respectively.

The activities were also evaluated. anti-HIV-1 and the toxicities of Compounds in two cell lines:

C8166 cells . The cells were grown in RPMI 1640 with 10% calf serum. 4 x 10 4 cells were mixed per microtiter plate with dilutions to the fifth of the compound before the addition of 10 DICC 50 units of strain III-B of HIV-1 and incubated for 5-7 days (Betbeder et al., Antiviral Chem. Chemother. 1, 241-247, 1990). Syncytium formation was examined 2 days after infection. Culture fluid was collected at 5-7 days and gp120 antigen production was measured by ELISA (Mahmood and Hay, J. Immunol. Meth., 151, 9-13, 1992). The EC50 is that concentration of drug [in µM] required to reduce the production of gp120 by 50%. The cell viability of infected and non-infected cells was evaluated by the MTT-Formazano method (Pauwels et al., J. Virol. Meth. 20, 309-321, 1988).

JM cells JM cells, which are relatively resistant to the antiviral effects of AZT and some of its derivatives, were infected with HIV-1 strains and the antiviral and toxic effects of the compounds were evaluated as for C8166 cells. Both strains of HIV-1 GB8 and IIIB were used, with no detectable differences in the observed endpoints.

Each analysis was carried out in duplicate, at less on two separate occasions, and the data expressed are the average of each separate analysis.

The compounds of the present invention have shown to be active against HIV-1 and HIV-2 in both TK + and TK - cells as It is illustrated in Table 2.

       \ vskip1.000000 \ baselineskip
    

TABLE 2

HIV-1 in C8166 / JM HIV-2 in EMF TK + / CEM TK - Compound CE_ {50} \ muM CE_ {50} CE_ {50} \ muM CE_ {50} C8166 JM EMC TK + EMC TK <-> 730 0.0008 0.0008 0.016 0.06 d4T 0.08 0.8 1.2 > 100 (comparative)

As expected, d4T (comparative) loses activity in kinase-free cells (especially EMF TK -), while compound 730 of the invention retains a good activity in both TK + and TK - versus HIV-1 and HIV-2. Compound 730 of the invention is> 1,000 times more potent than d4T in cells TK <->. Surprisingly, the compound is 100 times more powerful. than d4T in the analyzes with CEM TK -.

The potent activity of the compounds of the The invention is further supported by the data in Table 3, which illustrates the index of activity, toxicity and selectivity of a series of compounds of the present invention.

The enhanced antiviral potency and reduced cytotoxicity of phosphate derivatives lead to large improvements in the selectivity index [defined as CC 50 / EC 50], demonstrating the marked improvements in in vivo efficacy compared to d4T (comparative) .

The evidence that the compounds of this invention are acting by means of a different route to that of d4T or AZT is provided by the data in Table 4.

As you can see, while the power of d4T (comparative) is greatly reduced in strains resistant to nucleosides, the potency of the compounds of the present invention It stays long. Thus, it is clear that the compounds of the present invention are not acting primarily by means of conventional 5'-triphosphate nucleoside derivative.

MT4 cells (at 400,000 cells / ml) and the PBL cells (at 2,000,000 cells / ml) were exposed to different concentrations of 324 [H 3] and incubated at 37 ° C for 24 hours. Then the cells were washed twice with cold PBS and 400 µl of cold methanol was added to the cell pellet 66% After allowing to rest on ice for 10 minutes, the extract cell was centrifuged and the supernatant was analyzed by HPLC As shown in Table 5, the levels of Intracellular D4T-MP (monophosphate) increased proportionally based on the initial concentration of 324 in the three cell lines tested. However the increased levels of D4T-TP (triphosphate) decreased to the initial doses of 324 that were greater than 25 µM (for CEM and MT4 cells) or greater than 1.0 µM (for PBL). Surprisingly, a metabolite (called X) accumulated substantially and predominantly in all three cell types. The accumulation was proportional to the initial 324 concentration, and, again, it was lower in PBL than in CEM and MT4 cells.

When incubating 324 1 mM with elevated Pork liver esterase concentrations at 37 ° C in buffer Tris-HCl containing 5 mM MgCl2, was observed a time-dependent formation of a metabolite. These metabolites eluted simultaneously with the predominant metabolite (X) that was found in cell extracts after incubation of intact cells with 324 [H3]. He metabolite X corresponds to a compound of formula (10), where Y is oxygen, X 1 is NH, X 2 is oxygen, B is thymine, R 1 is Me, R2 is hydrogen.

The data of the extended range of compounds is presented in Table 6 (dT4 analogues) in which:

Comp. and Start: they refer to the reference numbers of the compounds;

And does group reference:

       \ vskip1.000000 \ baselineskip
    

       \ vskip1.000000 \ baselineskip
    

12

       \ vskip1.000000 \ baselineskip
    

Z: does reference to the groups T1 and T2;

B: does reference to the base of the heterocyclic nucleic acid, present in C1 'in β orientation; {} \ hskip0,3cm are used Conventional one-letter base codes; the substituents of the pyrimidine are in {} \ C5.

       \ newpage
    

The columns of data are, in order:

HIV-1 MT4: EC50 in µM for inhibition of HIV-1 in MT4 cells.

HIV-2 MT4: EC50 in µM for the inhibition of HIV-2 in MT4 cells.

CC50 MT4: CC 50 in µM for toxicity in MT4 cells.

IH-1 CEM: CE 50 in µM for HIV-1 inhibition in CEM cells.

HIV-2 EMC: EC50 in µM for inhibition of HIV-2 in CEM cells.

HIV-2 CEM-TK -: EC50 in µM for inhibition of HIV-2 in CEM / TK - cells.

CC50 CEM: CC 50 in µM for toxicity in CEM cells.

CE50 MSV: EC50 in µM for inhibition in MSV

MCC MSV: Minimum cytotoxic concentration in the MSV analysis

When the data in table 6 differs from those presented in Tables 2 to 5, the first data refer to the average result obtained from two or more repeated experiments, while the latter refer to the results individual experimental

       \ vskip1.000000 \ baselineskip
    

       \ vskip1.000000 \ baselineskip
    

       \ vskip1.000000 \ baselineskip
    

(Table goes to page next)

13

14

fifteen

16

17

18

19

twenty

twenty-one

22

In vivo test Inhibitory effects of test compounds on initiation of MSV-induced tumor formation in NRMI mice and over survival of NMRI mice inoculated with MSV

Mice infected with Sarcoma Virus Moloney [MSV] were treated daily with placebo, or with d4T [a one of the two doses] or with compound 324 at one of them [equimolar] dose.

NMRI mice two to three days old (weighing 2 grams) were inoculated subcutaneously (sc) in the left hind leg with 50 µL of MSV (100 foci-forming units, measured by in vitro determination of virus-induced transformation of murine C3H embryonic fibroblast cells). Within 4 or 5 days of infection, tumors developed and rapidly increased in volume with the additional aging of the mice. At 10-12 days after infection, the mice (weighing 5 to 6 grams) died of the viral infection. Drug treatment began 1 hour before virus infection, and the compound was also administered daily ip for 3 more days. The mean day of onset of the tumor (± standard deviation) and the average days of survival of the mice (± standard deviation) were calculated and the statistical significance of the average delay in tumor formation and the average of days were evaluated survival in the treated groups versus the untreated (control) group using a two-tailed Student's t-test.

While d4T failed to provide any detectable delay in the appearance of tumors or in death, it observed a significant effect of both parameters with a high dose of compound 324, and an effect on the first parameter at a low dose [Figure 1].

Claims (14)

1. A compound of formula (1):

         \ vskip1.000000 \ baselineskip
      

2. 3

         \ vskip1.000000 \ baselineskip
      

where:

Ar is a group aryl;

And it is oxygen or sulfur;

X1 se selects between O, NR 3, S, CR 3 R 4, CR 3 W 1 and CW 1 W 2 where R 3 and R 4 are selected

independently between hydrogen, groups alkyl and aryl; and W1 and W2 are heteroatoms;

X 6 is CH2 and X2 is selected (independently of X1) between O, NR 3, S, CR 3 R 4, CR 3 W 1 and CW 1 W 2

where R3 and R 4 are independently selected from hydrogen, groups alkyl and aryl; and W1 and W2 are heteroatoms;

X3 is -CR 1 R 2 - where R 1 and R 2 are selected independently between hydrogen, alkyl and aryl groups; X 4 it is oxygen;

X5 is absent;

Z is selected between O and NR 5, where R 5 is selected from hydrogen, alkyl and aryl groups;

J is selected between the alkyl groups;

Q is selected between O, NR 6, S, CR 6 R 7, CR 6 W 3 and CW 3 W 4, where R 6 and R 7 are selected

independently between hydrogen, groups alkyl and aryl; and W3 and W4 are heteroatoms;

T1 and T2 are connected to each other and together they are selected from among groups

         \ vskip1.000000 \ baselineskip
      

24

         \ vskip1.000000 \ baselineskip
      

B is a base of purine or pyrimidine

or a derivative or metabolite pharmaceutically acceptable thereof, the metabolite being a metabolite or remainder of the compound of formula 1 that results in a mode of transcriptase inhibition independent of resistance to nucleosides or nucleoside independent 5'-triphosphate shown by the compound of formula one. 2. A compound according to claim 1, where

And it is oxygen;

X1 is NH;

X3 is CHR1, where R1 is selected from H, alkyl groups and aryl; Y

Z is oxygen.

3. A compound of formula (10)

         \ vskip1.000000 \ baselineskip
      

25 or a derivative or metabolite pharmaceutically acceptable thereof, the metabolite being a metabolite or remainder of the compound of formula 10 that results in a reverse transcriptase inhibition mode independent of the nucleoside resistance or nucleoside independent 5'-triphosphate shown by the compound of formula 10. 4. A compound according to claim 3, where

And it is oxygen;

X1 is NH; Y

X3 is CHR1.

5. A compound according to any one of the claims 1 to 4, wherein

X2 is oxygen; Y

What is it oxygen.

6. A compound according to claim 5, wherein B is thymine. 7. A compound according to claim 6, wherein Ar, R1 and J are defined as follows: Compound from Reference Ar R1 J 323 4-EtPh I I 324 Ph I I 327 4-FPh I I 526 3-CF 3 Ph I I 546 3,5-Cl2 Ph I I 730 Ph I Bzl 776 2,4-Br2 Ph I I 779 F_5 Ph I I (Continuation) Compound from Reference Ar R1 J 862 Ph I Hexyl 863 Ph Bzl I 864 Ph CH_ {2} iPr I 865 Ph iPr I 866 Ph H I 867 Ph [CH 2] 2 SMe I 868 2,4Br2 Ph I Bzl 877 Ph Bzl Bzl 878 Ph Bzl tBu 892 Ph I Cyclohexyl 893 Ph I tBu 8. A compound according to any one of the claims 1 to 7, for use in a treatment method, prophylaxis or diagnosis of a viral infection. 9. The use of a compound according to any one of claims 1 to 7, in the manufacture of a medicament for the treatment or prophylaxis of a viral infection. 10. The use of a compound according to claim 9, wherein the viral infection comprises HIV. 11. A procedure for the preparation of a compound according to any one of claims 1 to 7, which comprises the reaction of a compound of formula (11) 26 with a compound of formula (12) 27 12. The use of a compound according to any one of claims 1 to 7, in the manufacture of a medicament for use in inhibiting a reverse transcriptase by a mode of action independent of nucleoside resistance or nucleoside independent 5'-triphosphate. 13. A pharmaceutical composition comprising a compound according to any one of claims 1 to 7 combined with a pharmaceutically acceptable excipient. 14. A method of preparing a composition pharmaceutical comprising combining a compound according to a any one of claims 1 to 7 with an excipient pharmaceutically acceptable.